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ABSTRACT 
Introduction 
Cardiomyopathy is an endemic disease in Africa that is a major contributor to the clinical 
syndrome of heart failure. The various forms of cardiomyopathies pose a great challenge in 
Africa for many reasons, including the difficulty of diagnosis and the scarcity of interventions 
such as heart transplantations in resource-poor environments. The aetiology of the 
cardiomyopathies had been unknown but various genetic abnormalities associated with 
cardiomyopathy have been unraveled. A previous whole exome sequencing project conducted 
in the United Kingdom (UK) had identified parvin alpha (PARVA) as a candidate gene in a South 
African family, ACM 8, with several members affected with arrhythmogenic right ventricular 
cardiomyopathy (ARVC).  
  
Hypothesis: We hypothesize that PARVA harbors novel genetic mutations that cause ARVC and 
other forms of cardiomyopathy.  
 
Aim: To screen the PARVA gene for mutations in a large panel of probands with ARVC and other 
cardiomyopathies and to validate the whole exome sequencing results obtained in the UK on a 
different sequencing platform. 
 
Methods and Results 
We investigated the ACM 8 family with three affected individuals (two severely affected 
children and the mother) for whom the genetic cause of the disease was unknown. Genetic 
analysis was previously performed at Newcastle in the UK using whole exome sequencing on an 
Illumina platform. In this analysis, the PARVA c.392A>T variant was identified as a possible 
cause of ARVC in this family. We expanded on this work by using high resolution melt (HRM) 
analysis and Sanger sequencing to screen all the available ACM 8 family members to determine 
segregation of the PARVA c.392A>T variant within this family. We observed that the phenotypic 
variability seen within this family cannot be explained by the PARVA c.392A>T variant alone and 
called into question the causative role of PARVA within this family We also screened the 
cardiomyopathy cohort consisting of 180 probands diagnosed with ARVC, dilated 
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cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM) and restrictive cardiomyopathy 
(RCM) in the Cardiovascular Genetics Laboratory. No definitive evidence of pathogenic PARVA 
variants was found any of the cardiomyopathy probands screened. We subsequently performed 
whole exome sequencing on this family to validate the UK findings ( Ion Torrent platform). We 
found that both affected individuals were homozygous for the PKP2 c.1162C>T mutation. PKP2 
is a gene known to cause ARVC, and the c.1162C>T mutation has been described as a founder 
mutation for autosomal dominant ARVC families of Afrikaner decent in South Africa. 
Conclusion 
While this study set out to validate the whole exome sequencing experiments conducted in 
family ACM 8 in the UK, we instead found the causal variant to be the previously reported PKP2 
c.1162C>T mutation. We also explored the possibility of PARVA as a causal gene for ARVC but 
no pathogenic PARVA mutations were identified.   
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CHAPTER 1: INTRODUCTION 
1.1. Structure and function of the heart 
The human heart is an organ that pumps blood throughout the body via the circulatory system, 
supplying oxygen and nutrients to the tissues, while removing carbon dioxide and other wastes 
(URL1). A healthy, adult heart is usually the size of an average clenched adult fist, but may vary 
due to a person’s age, size, and the condition of their heart. The heart is comprised of four 
chambers, namely the right ventricle, left ventricle, right atrium and left atrium (Figure 1.1) 
(URL2).  Surrounding the heart is a fibrous enclosure called the pericardium which holds the 
heart in place while allowing it to move as it beats. The wall of the heart is comprised of three 
layers: the inner endocardium, the middle myocardium, and the outer epicardium, with the 
myocardium being the thickest layer. The cardiac muscle is a specialized muscle which makes 
up the myocardium. It is composed of cardiomyocytes, which are specialized muscle cells that 
contract akin to other muscle cells, but unlike other muscle cells they generate and conduct 
electricity for contraction and coordination of the heart through the conduction system (URL3).  
 
   
 
 
 
 
 
Figure 1.1: Structure of the heart. The blue shading indicates deoxygenated blood received from the rest 
of the body while the red shading indicates oxygenated blood received from the lungs and pumped to 
the rest of the body (Adapted from URL4). 
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Blood from the body enters the heart via the superior and inferior venae cavae which empty 
oxygen-poor blood into the right atrium. Contraction of the atrium causes blood to flow 
through the tricuspid valve into the right ventricle. The tricuspid valve shuts when the right 
ventricle contracts in systole, thus preventing blood from flowing back into the right atrium. 
When the ventricle contracts, blood is ejected into the pulmonary artery through the pulmonic 
valve and flows to the lungs, where it is oxygenated. The oxygenated blood then returns to the 
heart through the pulmonary veins where it is emptied into the left atrium. As this atrium 
contracts, blood flows from the left atrium into the left ventricle via the open mitral valve. 
Contraction of the left ventricle leads to ejection of blood into the systemic circulation via the 
aorta (URL2). 
Compared to the atria, the ventricles are the more muscular pumping chambers that eject 
blood into the pulmonary or systemic circulation via the large arteries. The left atrium and the 
left ventricle have more muscle in their walls than the right side of the heart and are larger in 
size than the corresponding chambers on the right. This is because blood from the left side of 
the heart must be pumped to the rest of the body, while blood from the right side goes to the 
pulmonary circulation (URL2).  
 
1.2. Cardiomyopathy 
Cardiomyopathy is defined as a myocardial disorder in which the heart muscle is structurally 
and functionally abnormal, in the absence of coronary artery disease, hypertension, valvular 
disease and congenital heart disease sufficient to cause the observed myocardial abnormality 
(Elliott, Andersson et al. 2008).  
According to the European Society of Cardiology classification system for cardiomyopathies, the 
cardiomyopathies are grouped into specific morphological and functional phenotypes whereby 
each phenotype is sub-classified into familial and non-familial forms (Elliott, Andersson et al. 
2008, Arbustini, Narula et al. 2014). The main types of cardiomyopathy presented in this 
scheme are dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy 
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(ARVC), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and 
unclassified cardiomyopathies.   
In Africa, cardiomyopathy is an endemic disease that is a major contributor to the clinical 
syndrome of heart failure (Mayosi 2007). The cardiomyopathies pose a great challenge in Africa 
for many reasons, including the difficulty of diagnosis, which often requires specialized 
cardiological examinations and the scarcity of interventions such as heart transplantations in 
resource-poor environments. The high mortality related to these often irreversible heart 
muscle disorders, together with their high prevalence in societies still plagued by poverty and 
famine contributes to their burden (Akinkugbe, Nicholson et al. 1991). 
 
1.2.1 Dilated Cardiomyopathy (DCM) 
DCM is a heart muscle disease that is defined by the presence of left ventricular dilatation and 
left ventricular systolic dysfunction in the absence of abnormal loading conditions 
(hypertension, valve disease) or coronary artery disease sufficient to cause global systolic 
impairment (Figure 1.2). 
  
 
 
 
 
 
 
 
Figure 1.2: Comparison of a normal heart (left) with a DCM heart (right). A cross-section of each 
heart is presented, showing the ventricles (indicated) and the atria. The left ventricle is enlarged in 
DCM, and the left ventricular wall is stretched (URL5) 
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Classically, the disease starts in the left ventricle, where the heart muscle begins to dilate, 
stretch, and become thinner. Consequently, the inside of the chamber enlarges. This tends to 
advance to the right ventricle and later to the atria. Right ventricular dilation and dysfunction 
may be present but are not necessary for diagnosis (Elliott, Andersson et al. 2008). Dilation of 
the chambers causes the heart muscle to contract abnormally and the heart cannot pump 
blood effectively. This weakening of the heart causes a predisposition to progressive heart 
failure which has a 4 year mortality of 34% after onset of symptoms (Felker, Thompson et al. 
2000). DCM has been described to have distinctive clinical features that contrast with other 
forms of heart disease despite its unknown aetiology. Many patients exhibit emboli formation 
and subsequent infarctions, mostly in the viscera (Cosnett 1962, Cosnett and Pudifin 1964). In 
early paediatric reports, DCM was also shown to present with similar clinical and pathological 
manifestations as in adults (Stein, Shnier et al. 1964).    
Strict diagnostic criteria are lacking (Silverman and Aksut, 2015) but the diagnosis of DCM is 
made where there is evidence of dilation and impaired contraction of the left and/or both 
ventricles with left ventricular ejection fraction less than 40 percent or fractional shortening 
less than 25 percent (Richardson, McKenna et al. 1996). The disease is considered idiopathic if 
primary and secondary causes of heart disease such as myocarditis and coronary artery disease 
are excluded by evaluation including physical examination, careful medical history, laboratory 
testing results, echocardiography and coronary angiography (to exclude greater than 50 
percent obstruction of one or more coronary arteries) (Elliott 2000) (Cosnett 1962, Cosnett and 
Pudifin 1964). 
Reliable data on the incidence and prevalence of dilated cardiomyopathy are difficult to come 
by (Rakar, Sinagra et al. 1997) with the only formal estimate of DCM prevalence being a study 
that was conducted in Olmsted County, Minnesota from 1975 to 1984 that estimated its 
prevalence as of 1985 at 1:2,700 (Codd, Sugrue et al. 1989). This estimate was twice the 
estimated prevalence of HCM which was 1:5000 from the same cohort during the study period 
(Codd, Sugrue et al. 1989). Hershberger et al (Hershberger and Morales 1993) suggested the 
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frequency of DCM is equal to the established frequency of hypertrophic cardiomyopathy 
(1:500) or even greater at 1:250 (Hershberger and Morales 1993). In Africa, prior myocarditis, 
malnutrition, excessive alcohol consumption, subsequent myocarditis and heredity have been 
proposed as causes, and some or all of these factors may play a role in disease expression. 
Mechanical effects of fibrosis and the immunological response to myocardial damage are also 
likely contributory factors to progression of the disease (Watkins and Mayosi 2009). 
In contrast to more industrialised regions, there have been no population-based studies 
conducted to assess the prevalence of DCM in Africa and thus its true burden in Africa is 
unknown (Sliwa, Damasceno et al. 2005). Despite this, it is widely accepted that 
cardiomyopathy is pervasive, particularly among black Africans (Bradlow, Zion et al. 1964). 
Studies conducted in South African populations revealed that in a clinical series, DCM 
accounted for 11.6% to 37.5% of diagnoses of heart disease (Cosnett 1962, McGlashan 1988) 
and 15.4% to 48% of heart failure admissions (Powell and Wright 1965, Sliwa, Wilkinson et al. 
2008). In a necropsy series, DCM was the cause of death in 14.1% to 17% of cases of heart 
disease (Isaacson 1977, Steenekamp, Simson et al. 1992) and 12.7% of deaths from heart failure 
(Kallichurum 1969). In a study conducted by Ntusi et al, it was shown that DCM mortality is still 
relatively high despite modern medical and surgical intervention (Ntusi, Badri et al. 2011), and 
that some of the therapies being implemented such as the administration of digoxin drugs to 
the DCM patients, have not improved survival rates among patients. In contrast, these 
therapies seem to have a mortality risk associated with them (Rathore, Curtis et al. 2003).  
Cardiac transplantation is still a standard therapeutic option for advanced heart failure and was 
pioneered in South Africa (Beck 1978). Other therapies that have been proposed include 
palliative pericardiotomy for refractory heart failure (Lewis, Barnard et al. 1973) as well as 
treatment with thiamine and nicotinamide (Seftel 1973). The investigation of pentoxifylline for 
heart failure was perhaps the most standout input of South African investigators in the DCM 
treatment; this drug suppresses the immune response to DCM, particularly Tumor necrosis 
factor alpha60 (TNF-α60) and C-reactive protein (CRP) (Sliwa, Woodiwiss et al. 2004). While 
pentoxifylline has shown promise, a systematic review of these studies – which have been the 
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only randomised studies on the drug – concluded that although there was a trend towards 
reduced mortality, the results were not statistically significant, and larger trials were needed 
(Batchelder and Mayosi 2005). 
 
1.2.2 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 
ARVC is defined by the presence of right ventricular dysfunction which may be global or 
regional, with or without left ventricular disease, in the presence of histological evidence for 
the disease or electrocardiographic abnormalities in accordance with published criteria 
(McKenna, Thiene et al. 1994).  Unlike DCM, HCM, and RCM, ARVC is defined histologically by 
the presence of progressive replacement of right ventricular myocardium with adipose and 
fibrous tissue (Figure 1.3). This fibrofatty replacement is often confined to a ‘triangle of 
dysplasia’ comprising the right ventricular inflow, outflow, and apex. While these pathologic 
abnormalities can result in functional and morphological right ventricular abnormalities, they 
also produce a DCM phenotype when they manifest in the left ventricle. They can also be 
present in the absence of clinically detectable structural changes in either ventricle. 
 
 
 
 
 
 
 
Figure 1.3: Diagram comparing a normal heart on the left with an ARVC heart on the right. The ARVC 
heart has fibrofatty replacement as sites of myocyte detachment (Link, Laidlaw et al. 2014). 
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 ARVC usually starts causing symptoms by the third decade of life, with males manifesting 
symptoms of the disease more often than females (Corrado and Thiene 2006). Common 
presentations among patients include palpitations, dizziness and syncope. About a third of 
South African patients also experience chest pain, which makes ARVC an important 
consideration for clinicians evaluating young people with chest pain (Hendricks, Watkins et al. 
2010). 
The original 1994 International Task Force Criteria (TFC) for the clinical diagnosis of ARVC were 
based on structural, histological, electrocardiography (ECG), arrhythmic, and familial features of 
the disease (McKenna, Thiene et al. 1994). Abnormalities were subdivided into major and minor 
groups according to the specificity of their association with ARVC. Furthermore, the 1994 
criteria focused on right ventricular (RV) disease manifestations and stipulated the absence of 
or only mild left ventricular (LV) involvement because of the need to exclude common disorders 
such as ischemic heart disease and dilated cardiomyopathy (Marcus, McKenna et al. 2010). 
Thus, a definite diagnosis of ARVC, according to the 1994 task force criteria (McKenna, Thiene 
et al. 1994) was made based on two major criteria or one major and two minor criteria or four 
minor criteria from different categories. Borderline diagnosis of ARVC was dependent on one 
major criterion and one minor or three minor criteria from different categories while a possible 
diagnosis was called in the event of one major criterion or two minor criteria from different 
categories. ARVC diagnosis can be a challenge because its symptoms can be discreet for years 
during its earlier phases, which means that a close follow up with high index of suspicion and 
repeat evaluations is needed.  
Even in the South African cohort, who typically represented with advanced disease, 6% of 
subjects had a normal resting ECG at their last follow-up visit. Among the symptomatic patients, 
12% of them had no abnormalities at all on cardiac imaging and their diagnosis was based on 
family history, electrocardiographic abnormalities and molecular genetic tests; nevertheless, 
this is not a benign cardiomyopathy (Hendricks, Watkins et al. 2010) .  
An ARVC study conducted in South Africa by the ARVC Registry in South Africa gave practical 
implications of the disease (Watkins, Hendricks et al. 2009). Several Registry participants had 
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died by the end of the follow-up period (a median of around eight years). The annual mortality 
in the study was 2.8%, and the five-year cumulative mortality was 10%. On average, patients 
died two decades earlier than patients in France (Hulot, Jouven et al. 2004), thus the outcomes 
were worse compared to other parts of the world. There are several explanations for this, the 
most likely of which is that implantable cardioverter-defibrillators (ICDs), which are life-saving 
for ARVC patients, are under-utilized in South Africa. Furthermore, patients cannot always 
access the correct diagnosis and management of their disease. 
Although ARVC is uncommon, with an estimated prevalence of 1 in 5000 individuals, it is a 
frequent cause of sudden death in young people accounting for 11% of all cases and 22% of 
cases among athletes (Corrado, Basso et al. 1998, Tabib, Loire et al. 2003). In South Africa, the 
disease is present in all ethnic and racial groups and according to a study by Watkins et al. the 
cohort, consisting of 50 patients with definite ARVC, had the following ethnic variation: 80% 
white (40 patients), 10% mixed ancestry (5 patients), 8% black African (4 patients), and 2% 
Indian (1 patient) (Watkins, Hendricks et al. 2009). 
In two out of every three patients who died in the aforementioned ARVC study, arrhythmias 
were the cause of death, and to date no Registry participant who has received an ICD has died. 
From a practical outlook, these data advocate for the early use of ICDs in patients with syncope 
and sustained ventricular tachycardia as a way to prevent early mortality. Any patients with 
these symptoms and an ARVC diagnosis should be given top priority to be evaluated by a 
cardiologist (Hendricks, Watkins et al. 2010).  
The natural history of ARVC is poorly understood and thus it is difficult to define a definite 
therapeutic algorithm. The treatment is essentially observational and is therefore based on 
presentation. For primary prevention in high-risk patients and secondary prevention of sudden 
cardiac death in patients with sustained ventricular tachycardia or ventricular fibrillation, an ICD 
is recommended. The goal of therapy is to reduce the frequency and severity of arrhythmias for 
symptomatic relief. Beta-blockers are generally considered the first line of drug therapy. Some 
of the antiarrhythmic agents include flecainide, propafenone, sotalol, and amiodarone, alone or 
in combination. Sotalol is the most effective drug for inducible or noninducible ventricular 
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tachycardia. In young patients amiodarone may not be convenient because of side effects 
associated with long-term use (Wichter, Borggrefe et al. 1992). 
Pharmacotherapy is also used as an adjunct to ICD in selected patients with frequent life-
threatening arrhythmias. Lifestyle modification in form of avoiding vigorous exercise in affected 
persons is recommended as activity can trigger arrhythmias. It is also advisable to avoid cardiac 
stimulants such as caffeine and pseudoephedrine (URL6). 
 
1.2.3. Hypertrophic Cardiomyopathy (HCM) 
HCM is characterised macroscopically by left ventricular hypertrophy (LVH) in the absence of a 
discernible cause, such as hypertension or aortic stenosis (Figure 1.4) and myocyte and 
myofibrillar disarray for histological assays (Mayosi 2005). 
  
  
 
 
 
 
 
 
 
 
Figure 1.4: Comparison of a normal heart (left) with a HCM heart (right). In the cross sectional view 
above, the HCM heart presents with increased left ventricular wall thickness (URL13). 
 
With the LVH there is an enlargement of the heart muscle notably at the interventricular 
septum leading to cardiac dysfunction (Green, Wakimoto et al. 2016). The LVH occurs in a non-
dilated ventricle in the absence of other cardiac or systemic disease that might lead to the 
observed magnitude of increased LV wall thickness, such as pressure overload caused by 
F
i
g
u
r
e
 
1
.
4
: 
C
o
m
p
a
r
i
s
o
n
 
o
f 
a
 
n
o
r
m
a
l 
 10 
 
persisting hypertension or storage disorders including amyloidosis and Fabry disease (Cirino 
and Ho 1993). The clinical manifestations of HCM range from asymptomatic LVH, progressive 
heart failure to sudden cardiac death (SCD), and vary even amongst individuals within the same 
family (Cirino and Ho 1993).  
 
The diagnosis of HCM depends on an abnormal thickening of the heart, but the earliest signs of 
disease are hyperdynamic contraction and impaired relaxation (Green, Wakimoto et al. 2016). 
Its diagnosis is most often established with noninvasive cardiac imaging, including 
echocardiography and/or cardiac magnetic resonance imaging (cardiac MRI) (Cirino and Ho 
1993). The diagnosis can also be made by pathognomonic histopathologic findings in cardiac 
tissue, including myocyte disarray and fibrosis (Cirino and Ho 1993). In a familial involvement 
HCM diagnosis can be made through family history and molecular genetic testing, focusing on 
genes that encode different components of the sarcomere (Cirino and Ho 1993). 
In general medical practice the disease may affect as many as 1 in 500 individuals in the general 
population (Mayosi 2005) with a  prediction of approximately 600,000 persons with HCM in the 
United States (US) making it one of the most common monogenic cardiovascular disorders 
(Cirino and Ho 1993). It is the third most common form of cardiomyopathy in Ghana, after DCM 
and endomyocardial fibrosis (EMF) (Amoah and Kallen 2000). In Ethiopia, it accounts for 34% of 
all cardiomyopathies diagnosed at echocardiography (Abegaz 1990).  
The aim of treatment is to relieve symptoms and prevent SCD in people at high risk. The 
severity of symptoms determines the specific treatment to be administered. Some of the 
available treatment options include medication to slow the heart rate and control heart 
rhythm, septal myectomy and ablation to improve the symptoms and ICD to continuously 
monitor and restore heart rhythm. The ICD option is applicable to patients who are at risk of 
SCD because of abnormal heart rhythm (URL4).  
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1.2.4. Restrictive Cardiomyopathy (RCM) 
RCM is a rare disease of the myocardium in which the principal abnormality is diastolic 
dysfunction—specifically, restricted ventricular filling. Patients typically have increased left 
ventricular diastolic stiffness, which may lead to diastolic heart failure (Figure 1.5). 
 
 
 
 
 
 
 
Figure 1.5: A diagrammatic comparison of a normal heart, on the left, with a restrictive cardiomyopathy 
heart. The restrictive cardiomyopathy heart has stiff ventricles but not necessarily thickened (URL14).  
 
The left ventricle cannot fill sufficiently at normal diastolic pressures, leading to reduced cardiac 
output due to reduced left ventricular filling volume. Systolic function usually remains normal, 
at least early in the disease. Wall thickness may be increased secondary to myocardial 
infiltration (e.g., in amyloidosis) or the left ventricular wall is stiff due to fibrosis (e.g. EMF).  
The clinical presentation of RCM may be confused with that of constrictive pericarditis because 
patients might actually have RCM while presenting with symptoms typical of constrictive 
pericarditis (URL6). In respect to history and clinical profile, the two may be indistinguishable. In 
addition, both conditions can coexist in the same patient; for example, radiation therapy affects 
the myocardium as well as the pericardium. The distinction between the two conditions may be 
made on echocardiography, cardiac catheterization and endomyocardial biopsy (URL6). 
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RCM accounts for approximately 5% of all cases of primary heart muscle disease (URL6) and is 
difficult to define because restrictive ventricular physiology is present in a wide range of 
different pathologies. The exact prevalence of RCM is unknown but it is probably the least 
common type of cardiomyopathy (Elliott, Andersson et al. 2008). In Africa, EMF, a form of RCM 
is a relatively common cause of heart failure in equatorial Africa (Silverman and Aksut 2015).  
The cause of RCM determines its progression and treatment is often unsatisfactory. It may be 
idiopathic, familial, or result from a systemic disorder, such as amyloidosis. Diuretics, 
vasodilators, angiotensin-converting enzyme inhibitors, and anticoagulation may be indicated 
for managing restrictive cardiomyopathy (URL6). Prognosis is generally poor with progressive 
deterioration. Patients who are refractory to supportive therapy usually die of low-output 
cardiac failure unless cardiac transplantation is performed.  
 
1.3. Molecular genetics of cardiomyopathy 
The aetiology of the cardiomyopathies had been unknown but various genetic abnormalities 
associated with cardiomyopathy have been unraveled. Candidate gene approaches which 
focused on the genes encoding proteins which interact with products of the previously 
identified disease genes have been successful in identifying novel disease genes (Kimura 2016). 
As shown in Table 1.1 many different disease genes been identified to date. The overlapping of 
disease genes for different clinical types is noteworthy (McNally, Golbus et al. 2013). 
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Table 1.1: Disease genes for hereditary cardiomyopathy (McNally, Golbus, & Puckelwartz, 2013) 
Condition Gene 
HCM/DCM/LVNC 
DCM/HCM/ARVC 
HCM/DCM/RCM 
DCM 
DCM/HCM 
ARVC/DCM 
DCM/LVNC 
DCM/LVNC 
DCM/HCM 
DCM/HCM/LVNC 
RCM/DCM/HCM 
 
Myosin-7 (MYH7) 
Titin (TTN) 
Cardiac Troponin T type 2 (TNNT2) 
Titin cap (Tcap) 
Alpha-actinin (ACTN) 
Desmoplakin (DSP) 
Lamin A/C (LMNA) 
Tafazzin (TAZ) 
Cysteine and glycine-rich protein 3 (CSRP3) 
Alpha-actin cardiac muscle 1 (ACTC1) 
Troponin I, cardiac muscle (TNNI3) 
LVNC-Left ventricular non-compaction 
 
1.3.1 DCM 
Only a minority (about 30%) of patients with DCM have evidence of familial segregation 
(Grunig, Tasman et al. 1998). Moreover, DCM is a feature of syndromic disorders, often with 
accompanying skeletal and limb-girdle myopathies. It was this co-existence of DCM and skeletal 
myopathy in Duchenne’s and Becker’s muscular dystrophies that lead to the discovery of 
dystrophin defects as a cause of X-linked DCM without obvious skeletal involvement, (Franz, 
Muller et al. 2000). This co-existence also lead to the consequential speculation that familial 
DCM is a ‘cytoskeletopathy’ (Towbin 1998). 
This proposal was also reinforced by additional studies in other skeletal myopathy DCM 
phenocopies, which implicated more proteins that make up the cytoskeleton, the internal 
structure of the cell. It was not only the internal cytoskeleton that was responsible, because 
 14 
 
proteins that form part of the extracellular matrix function in cell-to-cell contact at myocyte 
junctions have also been implicated in DCM. Proteins such as lamin A/C and emerin that 
stabilize the membrane around the cellular nucleus and those that connect these elements 
were also found to be defective in patients with dilated hearts (Figure1.6) 
 
 
 
 
 
 
 
 
 
Figure 1.6: Cellular localization of proteins involved in cardiomyopathy (Towbin and Bowles 2002) 
 
Up to one-third of individuals who have DCM inherit it from their parents but often its cause is 
unknown. Of the known cases, mutations in cytoskeletal, intercalated disc protein, sarcomeric 
protein, Z-band and nuclear membrane genes are responsible for autosomal dominant forms of 
the disease (Table 1.2). Patients with mitochondrial cytopathies and inherited metabolic 
disorders such as haemochromatosis may also have DCM (American Heart Association 2016).  
F
i
g
u
r
e 
1
.
6
: 
C
e
ll
u
l
a
r 
l
o
c
a
li
z
a
ti
o
n 
o
f 
p
r
o
t
e
i
n
s 
i
n
v
o
l
 15 
 
Table 1.2: Genes associated with DCM 
Condition Gene Proportion (%) of inherited 
cardiomyopathy caused by 
pathogenic variants of genes  
Autosomal dominant DCM Titin (TTN) (Gerull, Gramlich et al. 2002) 
Prelamin A/C (LMNA) (Fatkin, MacRae et al. 
1999) 
Myosin-7 (Kamisago, Sharma et al. 2000) 
Myosin-6 (Carniel, Taylor et al. 2005) 
Sodium channel protein type 5 subunit alpha 
(SCN5A) (McNair, Ku et al. 2004) 
Myosin-binding protein C, cardiac-type 
(MYBPC3) (Daehmlow, Erdmann et al. 2002) 
Troponin T, cardiac muscle (TNNT2) (Hanson, 
Jakobs et al. 2002) 
Ankyrin repeat domain-containing protein 1 
(ANKRD1) (Duboscq-Bidot, Charron et al. 
2009) 
Vinculin (VCL) (Olson, Illenberger et al. 2002) 
 
10-22 
6 
4.2 
4.3 
2-4 
 
2-4 
 
2.9 
 
2.2 
 
1 
X-linked Dystrophin (DMD) (Towbin, Hejtmancik et al. 
1993) 
Tafazzin (TAZ) (Bione, D'Adamo et al. 1996) 
Still Unknown 
Still Unknown 
Autosomal recessive DCM Troponin I, cardiac muscle (TNNI3) (Murphy, 
Mogensen et al. 2004) 
<1 
 
The discovery that a number of cytoskeletal proteins form substrates for proteases expressed 
by viruses known to cause cardiac dilation (Shoeman, Kesselmier et al. 1991, Badorff, Berkely et 
al. 2000) may indicate that the causative principle involved in DCM may be instability at any 
structural point throughout the integrated organization of the cardiac syncytium. 
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Several of the sarcomeric protein-encoding genes originally implicated in HCM (Section 1.3.3) 
have also been found to be defective in some DCM cases, making the etiological distinction 
between these two disorders unclear (Olson, Michels et al. 1998, Gerull, Gramlich et al. 2002). 
It may be that these particular mutations cause DCM rather than HCM because of their 
different involvement in the functional domains of these proteins, or simply because the 
sarcomere itself inherently also forms part of the integrated internal structure of these cells. 
To add to this complexity, DCM is seemingly also not purely a disease of cell architecture, but 
that energy metabolism could play a major role as well, as is now postulated for HCM. It has 
long been known that mitochondrial DNA defects are associated with DCM (Grasso, Diegoli et 
al. 2001, Khogali, Mayosi et al. 2001). Morphometric studies of mitochondria in cardiac biopsies 
from DCM and HCM has produced data which suggested that the mitochondria of DCM hearts 
showed decreased activity, while those from HCM hearts showed increased activity (Tashiro, 
Masuda et al. 1990). An establishment of whether these mitochondrial defects are the cause of 
the cardiac phenotype, or a consequence of it, has been difficult to prove.  
In Africa, several gene association studies have been conducted, which suggest that heredity 
may be influential in the susceptibility to DCM in Africans (Mayosi 2007). An association with 
Human Leukocyte Antigen - antigen D Related (HLA‐DR1) has been reported in South African 
patients which suggest that genetically determined immune‐response factors have a role in the 
pathogenesis of some people with DCM (Maharaj and Hammond 1990). A common 
mitochondrial DNA polymorphism c.16189T>C has also been found to be a genetic risk factor 
for DCM in a South African cohort, with a population attributable risk of 6% (Khogali, Mayosi et 
al. 2001). These genetic associations suggest that they may represent genetic risk factors for 
DCM worldwide as they have been replicated in other populations (Marin-Garcia, Zoubenko et 
al. 2002, Rodriguez-Perez, Fragoso et al. 2007). Mutation screening studies in South African 
patients with idiopathic and familial DCM have identified families with early onset DCM caused 
by a known mutation in the troponin T gene (c.471C>T) (Mayosi 2007) as well as in the 
Phospholamban (PLN) gene (Fish et al 2016), but did not show mutations in the cardiac and 
skeletal actin genes (Mayosi, Khogali et al. 1999). 
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1.3.2 ARVC  
A familial background has been demonstrated in over 50% of ARVC cases (Corrado and Thiene 
2006). The disease is usually inherited as an autosomal dominant trait with incomplete 
penetrance and variable expression. In 1994 the first chromosomal locus (14q23-q24) was 
associated with ARVC after clinical evaluation of a large Italian family (Rampazzo, Nava et al. 
1994). Afterwards, linkage analysis provided evidence for genetic heterogeneity with sequential 
discovery of several ARVC loci on chromosomes 1, 2, 3, 6, 10, 12, and 14.  
Autosomal recessive forms of ARVC, for example Naxos and Carvajal syndromes are recognized, 
but the majority of cases are caused by autosomal dominant inherited mutations in genes 
encoding plakophilin 2 (PKP2) and other proteins of the cardiomyocyte desmosome. Mutations 
in transforming growth factor-beta and ryanodine receptor genes may be associated with an 
ARVC phenotype (Table 1.3) In Naxos disease, there is a cosegregation of cardiac (ARVC), skin 
(palmoplantar keratosis), and hair (woolly hair) abnormalities which have been mapped on 
chromosome 17 (locus 17q21)(Rampazzo, Nava et al. 1994). 
Table 1.3: Genes associated with ARVC (Haugaa, Haland et al. 2016) 
Gene Proportion (%) of inherited cardiomyopathy 
caused by pathogenic variants of genes 
Desmoplakin (DSP) (Andreasen, Nielsen et al. 2013) 
Desmoglein 2 (DSG2) (Ackerman, Priori et al. 2011) 
Plakophilin 2 (PKP2) (Ackerman, Priori et al. 2011) 
Ryanodine receptor 2 (RYR2) (Andreasen, Nielsen et al. 2013)  
Plakoglobin (JUP) (Andreasen, Nielsen et al. 2013) 
Transmembrane protein 43 (TMEM43) (Andreasen, Nielsen et al. 
2013) 
Transforming growth factor-beta (TGF- ß) (Ackerman, Priori et al. 
2011) 
2-12 
5-10 
25-40 
Unknown 
Unknown 
Unknown 
Unknown 
 
Endurance exercise is a known risk factor of ARVC; in fact, 28% of patients in a South African 
ARVC cohort were professional endurance athletes at some point in their lives (Hendricks, 
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Watkins et al. 2010). Previous human and animal studies have demonstrated that, if an 
individual is genetically predisposed to ARVC, endurance exercise is an important 
environmental factor that leads to ARVC development (Heidbuchel, Hoogsteen et al. 2003, 
Kirchhof, Fabritz et al. 2006). Because of this, it is important that endurance athletes are 
screened for heart disease, before and during their sporting careers. 
Initial observations suggest that gap junction function is altered by the mechanical defect of the 
desmosomes. Evidence of myocyte loss or clinical evidence of right ventricular dysfunction may 
present before electrocardiographic (ECG) changes and arrhythmias (Kaplan, Gard et al. 2004). 
It has been proposed that similar clinical phenotypes occur that are based on disruption of a 
‘final common pathway’ by mutations in genes encoding proteins in the defined desmosomal 
pathway (Vatta, Marcus et al. 2007). Examination of the pathogenesis in relation to 
arrhythmogenesis and disease progression is facilitated by identifying the genetic basis of ARVC 
(Tsatsopoulou, Protonotarios et al. 2006).  
Seven genes have been identified in association with ARVC: plakoglobin (JUP) (McKoy, 
Protonotarios et al. 2000), desmoplakin (DSP) (Norgett, Hatsell et al. 2000), plakophilin-2 (PKP2) 
(Gerull, Heuser et al. 2004), desmoglein-2 (DSG2) (Awad, Dalal et al. 2006, Pilichou, Nava et al. 
2006), desmocollin-2 (DSC2) (Syrris, Ward et al. 2006), transforming growth factor beta-3 
(TGFß3) (Beffagna, Occhi et al. 2005) and transmembrane protein 43 (TMEM43) (Merner, 
Hodgkinson et al. 2008). In patients with an arrhythmic presentation, mutations in ryanodine 
receptor 2 (RYR2) have been reported in ARVC in the absence of significant 
electrocardiographic or structural abnormalities. At present, catecholaminergic polymorphic 
ventricular tachycardia is considered a disorder distinct from ARVC (Awad, Calkins et al. 2008). 
McKoy and colleagues identified the first disease-causing gene, JUP, in patients with Naxos 
disease. The gene encodes the desmosomal protein plakoglobin which is a major constituent of 
the cell adhesion junction. Its discovery suggested that ARVC is a cell-to-cell junction disease 
and stimulated the research of other related genes (McKoy, Protonotarios et al. 2000). 
DSP was the first desmosomal protein gene to be associated with the more common autosomal 
dominant form of ARVC by Rampazzo et al (Rampazzo, Nava et al. 2002). Gerull et al (2004) 
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identified 25 different mutations in the gene encoding PKP2. Recently, DSG2 mutations have 
been found in 10% of ARVC unrelated probands (Pilichou, Nava et al. 2006). 
Autosomal dominant ARVC has been linked to other genes unrelated to cell adhesion complex, 
such as the gene RyR2and TGFβ3 the latter of which is responsible for regulation of the 
production of extracellular matrix components and modulates expression of genes encoding 
desmosomal proteins (Corrado and Thiene 2006). 
It is still unclear how the mutations of PKP2 and more broadly of desmosomal protein genes 
cause disease. It has been hypothesized that the lack of normal protein or the incorporation of 
mutant protein into cardiac desmosomes may invoke myocyte detachment at the intercalated 
discs, particularly under conditions of mechanical stress, like that occurring during competitive 
sports activity (McKoy, Protonotarios et al. 2000). Consequently, there is a progressive myocyte 
death with subsequent repair by fibrofatty replacement. Life-threatening ventricular 
arrhythmias may occur either during the accelerated phase of myocyte death as abrupt 
ventricular fibrillation or later in the form of scar-related macro-reentrant ventricular 
tachycardia. To date, it is still unclear why myocytes are replaced by fibro-fatty tissue, or why 
the right ventricle is most severely affected. However, It is clear from molecular genetic studies 
in ARVC families that the genes implicated so far are not the only ones responsible for this 
cardiac phenotype, and it is possible that with identification of more ARVC-causing genes, these 
two features of the disease may become more readily understood (Moolman-Smook, Mayosi et 
al. 2003). 
Genetic testing is designated for symptomatic patients with ARVC and family members of a 
patient with a positive mutation. Relatives with more than one genetic variant are at a higher 
risk of developing clinical disease, potentially an important determinant of the phenotypic 
heterogeneity seen within families with ARVC (Quarta, Muir et al. 2011). At present, genetic 
testing is available for seven types of abnormalities (DSC2, DSG2, DSP, JUP, PKP2, RYR2 and 
TMEM43) (URL 7). 
Because ARVC runs in families, there is an urgent need to screen the first-degree relatives of 
affected individuals. Death is potentially preventable if there is early diagnosis of the condition 
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and high-risk individuals are promptly referred for consideration for ICD implantation. Genetic 
testing yields an answer in one out of four cases and is available in South Africa through the 
ARVC Registry at the University of Cape Town (Hendricks, Watkins et al. 2010). Desmosomal 
gene mutation is seen in 40%-50% cases and the clinical application of genetic testing is limited 
owing to multiple gene mutations and variable penetrance, requiring long-term follow-up (Sen-
Chowdhry, Syrris et al. 2007, Cowan, Morales et al. 2008) . 
The ARVC registry of South Africa report has made several key observations about the genetic 
causes of ARVC. Firstly, 30% of participants in the study had a family member who was also 
affected. For the purposes of the HeartRhythm report, genetic analysis was focused on the 
most common causative gene, PKP2. Of the DNA analyzed, 25% had a PKP2 gene defect that 
caused disease (Hendricks, Watkins et al. 2010); one mutation in particular, PKP2 c.1162C>T,  
was present in four South African probands of European origin which suggested a founder 
effect (Watkins et al., 2009). 
 
1.3.3 HCM 
HCM is recognized as an autosomal dominant disorder that is caused by more than 1400 
different mutations in at least eight different genes that code for sarcomeric proteins 
(Adalsteinsdottir, Teekakirikul et al. 2014) (Table 1.4). 
Table 1.4: Genes that cause HCM 
Gene Proportion (%) of inherited 
cardiomyopathy caused by 
pathogenic variants of genes 
Myosin-7 (MYH7) (Marian and Roberts 2001)  
Myosin-binding protein C, cardiac type (MYBPC3) (Marian and Roberts 2001) 
Troponin T, cardiac muscle (TNNT2) (Richard, Charron et al. 2003) 
Troponin I, cardiac muscle (TNNI3) (Marian and Roberts 2001) 
Tropomyosin alpha-1 chain (TPM1) (Marian and Roberts 2001) 
Myosin light chain 3 (MYL3)  (Marian and Roberts 2001) 
Myosin-6 (MYH6) (Jiang, Wakimoto et al. 2013) 
35-50 
20-25 
4 
20 
5 
5 
Unknown 
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Telethonin (TCAP) (Bos, Poley et al. 2006) 
Titin (TTN) (Bos, Poley et al. 2006) 
Myozenin-2(MYOZ2) (Ruggiero, Chen et al. 2013) 
Unknown 
Less than 5 
Unknown 
 
Earlier studies suggesting that only 50% of HCM was familial did not consider incomplete 
penetrance of the disease mutations, and that individuals may carry a causal mutation with 
mild or intermittently indiscernible HCM manifestations. With such carriers, their offspring are 
however still at a 50% risk of inheriting the mutation and may well manifest the disease 
(Mayosi 2005). The large families with multiple individuals clearly affected with uncomplicated 
HCM, as described in the early to mid-1900s (Teare 1958, Pare, Fraser et al. 1961) made this 
cardiomyopathy most amenable to molecular genetic analysis. Over the last decade, it has been 
demonstrated that HCM is a ‘sarcomeropathy’ (Thierfelder, Watkins et al. 1994).  Autosomal 
disorders that present in the young include Noonan and LEOPARD syndromes (dominant) and 
Friedreich’s ataxia (recessive) (Elliott and McKenna 2004).  
Although extreme hypertrophy is still a predictor of poor prognosis (Spirito, Bellone et al. 2000), 
hypertrophy and the risk of sudden cardiac death (SCD) are unrelated features (Moolman, 
Corfield et al. 1997, Moolman-Smook, De Lange et al. 2000). In fact, it was found that defects in 
some of these sarcomeric protein-encoding genes, such as TNNT2, often cause minimal 
hypertrophy and a high risk of sudden death. Interestingly, these sarcomeric encoding genes 
have been associated with early SCD (Watkins, McKenna et al. 1995, Moolman, Corfield et al. 
1997, Varnava, Baboonian et al. 1999, Moolman-Smook, De Lange et al. 2000). In a South 
African study, it was found that this was especially true in young male carriers of the TNNT2, 
c.8772C>T (R92W) mutation (Moolman, Corfield et al. 1997, Moolman-Smook, De Lange et al. 
2000).  
In addition, there have been indications that some of the morphological variants of 
hypertrophy are associated with specific genes or mutations. For instance, the TNNT2, 
c.8772C>T mutation has been associated, in Japanese patients, with the DCM-like variant with 
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early cardiac decompensation and progression from hypertrophy to dilation (Fujino, Shimizu et 
al. 2001). 
Studies of the functional effects of these mutations indicated that the encoded faulty proteins 
interfere with the function and the structure of the sarcomere, and may directly give rise to 
widespread myofibrillar and myocytic disarray, characteristic of HCM (Marian, Yu et al. , 
Varnava, Elliott et al. 2001). These functional studies also revealed that most HCM-causing 
defects result in abnormal calcium (Ca2+) sensitivity, (Redwood, Moolman-Smook et al. 1999) 
supporting the earlier observation of altered Ca2+ handling by HCM hearts (Paulus, Goethals et 
al. 1992, Schotten, Voss et al. 1999). 
In South Africa, however, there are three recurring or founder mutations that have been found 
in 45% of genotyped patients with European and mixed ancestry (Cantlay, Shokrollahi et al. 
1999). Consequently, South African patients with HCM referred for molecular diagnosis are 
initially screened for the three founder mutations (MYH7 c.1208G>T, MYH7 c.2389G>A, and 
TNNT2 c.274C>T). Only in the absence of these founder mutations is extensive screening done 
(Moolman-Smook, Mayosi et al. 2003). Experience elsewhere in the world has elucidated 
numerous mutations in the sarcomeric protein genes, such that many families have a conserved 
mutation that is unique to them (Moolman-Smook, De Lange et al. 1999). 
Our research group published a paper in 2016 describing the genetic features and outcome of 
HCM patients in South Africa whose clinical presentation, echocardiographic and 
electrocardiographic findings were obtained from the Cardiac Clinic at Groote Schuur Hospital; 
clinical presentation was similar to that reported in other studies (Ntusi et al., 2016). Targeted 
re-sequencing  was performed on 43 HCM patients and included 15 genes known to cause 
HCM: cardiac myosin binding protein C (MYBPC3), cardiac β-myosin heavy chain (MYH7), 
TNNT2, cardiac troponin I (TNNI3), regulatory light chain of myosin (MYL2), essential light chain 
of myosin (MYL3), tropomyosin 1 (TPM1), phospholamban (PLN), α-actin (ACTC1), cysteine and 
glycine-rich protein 3 (CSRP3), AMP-activated protein kinase (PRKAG2), α-galactosidase (GLA), 
four-and-a-half LIM domains 1 (FHL1), lamin A/C (LMNA) and lysosome-associated membrane 
protein 2 (LAMP2). Ten of 35 index cases had disease-causing mutations in only MYH7 (six cases 
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or 60%) and MYBPC3 (four cases or 40%) but not in the other 13 genes screened. The genetic 
screening gave a 29% yield of causal genetic mutations in South African HCM cases (Ntusi et al., 
2016).  
Up until 2000, any causative connection between phenocopies of HCM, which do not feature 
sarcomeric disruption, and classic HCM remained elusive, when mutations in the 5ı-activated 
AMP protein kinase (AMPK) gene were found in individuals featuring HCM and Wolf-Parkinson-
White syndrome (Blair, Redwood et al. 2001). The AMPK enzyme acts as the fuel gauge of the 
myocyte, sensing when adenosine triphosphate (ATP) levels are too low, and activating 
molecular pathways that lead to increased energy production (Winder and Hardie 1999, Hardie 
and Hawley 2001). This has led to the proposal that the common basic aetiological principle of 
cardiac hypertrophies, whether in HCM or in HCM-phenocopies, is related to an imbalance in 
energy supply and demand (Blair, Redwood et al. 2001). Whatever the primary cause of the 
energy inequality, prolonged decreased ATP levels will impede Ca2+ re-uptake from the 
cytoplasm into the sarcoplasmic reticulum by the Ca2+ ATPase which lead to Ca2+ related 
activation of hypertrophic and arrhythmic pathways(Spindler, Saupe et al. 1998, Somura, Izawa 
et al. 2001). 
 
1.3.4 RCM 
An autosomal dominant mode of inheritance is a hallmark of familial RCM, which in some 
families is caused by mutations in the TNNI3. In other families, RCM is caused by mutations in 
the desmin (DES) gene, normally associated with skeletal myopathy, which is linked to 
conduction defects. In rare cases, autosomal recessive inheritance can be seen in familial 
disease such as haemochromatosis caused by mutations in the Haemochromatosis (HFE) gene, 
or with X-linked inheritance (such as Anderson–Fabry disease) (Elliott, Andersson et al. 2008). 
MYH7, TNNT2 and TNNI3 mutations have been associated with RCM, HCM and DCM. The 
molecular basis of the differences between RCM and HCM associated mutations was that the 
RCM associated mutations showed much greater Ca2+ sensitization than the HCM associated 
mutations, as demonstrated for TNNT2 (Pinto, Parvatiyar et al. 2008) and TNNI3 (Yumoto, Lu et 
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al. 2005) mutations. In accordance with these findings, it was reported that restrictive 
phenotype (RCM-like HCM) was uncommon in HCM and may represent a poor prognosis form 
of HCM with severe diastolic dysfunction (Kubo, Gimeno et al. 2007). Alternatively, a gene dose 
effect could explain the difference between RCM-associated mutations and DCM-associated 
mutations. For example, a mutation in TNNI3 was observed in association with DCM when 
homozygous (Mogensen, Kubo et al. 2003), but was found as a heterozygous mutation in RCM 
patients (Murphy, Mogensen et al. 2004).  
 
1.4 Work leading to this thesis 
In a study conducted by Dr Mzwandile Mbele through the Cardiovascular Genetics Laboratory 
at the Hatter Institute For Cardiovascular Research at the University of Cape Town, an ARVC 
proband (ACM 8.3) was screened for mutations in the desmosomal genes PKP2, DSG2, DSP, 
DSC2 and JUP (Mbele,2014), but no mutations were found in any of these genes.  
 
This family was subsequently prioritized for whole exome sequencing by Dr Mbele as he set out 
to identify the genetic cause of the disease within this family. The whole exome sequencing 
experiment yielded a final candidate gene list which contained 13 variants but only two variants 
were reported to possibly be causative of ARVC. These variants occurred in the genes parvin 
alpha (PARVA) and high mobility group-box containing 3 (HMGXB3), neither of which had been 
reported in association with ARVC before. The PARVA c.392A>T (p.D131V) mutation was 
considered to be a more probable candidate gene for ARVC  based on the role of the PARVA 
protein as a cell adhesion molecule, rare PARVA mutations observed in the general population 
(1 in 12227 population controls), evolutionary conservation of the amino acid change and 
predicted deleterious effect on protein function. The HMGXB3 variant was purported to play a 
modifying role based on the biological significance of PARVA as a plausible ARVC gene, thus it 
was not pursued further.  
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1.5. Hypothesis 
A previous whole exome sequencing project completed in the United Kingdom (UK) had 
identified PARVA as a disease causing gene in a family with ARVC. We hypothesize that PARVA 
might be a new gene not only for ARVC but for other cardiomyopathies as well.  
 
 
 
 
 
 
1.6. Aims 
The aims of the study were to:  
1. Validate the whole exome sequencing results obtained in the UK on the ACM8 family. 
2. Screen for PARVA mutations in a large cohort of 180 probands diagnosed with ARVC, 
DCM, HCM and RCM. 
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CHAPTER 2: CANDIDATE GENE ANALYSIS OF PARVA 
2.1. Introduction 
In 2012, at the University of Newcastle upon Tyne in the United Kingdom (UK), Dr Mzwandile 
Mbele performed whole exome sequencing on two severely affected siblings on a South African 
family with ARVC, referred to as ACM 8. The proband, numbered ACM 8.3 and her younger 
brother ACM 8.4 (Figure 2.1) were diagnosed with ARVC at the ages of 10 years and 12 years, 
respectively.  Their parents, ACM 8.2 (mother) and ACM 8.1 (father) as well as older brother 
(ACM 8.9) did not meet the diagnostic criteria for ARVC at the time.  This family was prioritized 
for whole exome sequencing as  no causative genetic mutation had been found on routine 
genetic screening of the five desmosomal genes known to cause ARVC (i.e. PKP2, DSG2, DSP, 
DSC2 and JUP) (Watkins, Hendricks et al. 2009).  
Figure 2.1: Pedigree of the ACM 8 family with ARVC. Circles represent females. Squares represent males. 
Clear circles and squares represent unaffected family members. Black circles and squares represent 
affected family members. Crossed symbols represent deceased members of the family. The circle in red 
represents a family member whose blood was not available for DNA analysis.  
 
In his whole exome sequencing experiment, Mbele used the Illumina NGS platform and after 
the filtering processes, found that 13 variants (five homozygotes and eight heterozygous) (Table 
2.1) were shared by the two affected individuals, ACM 8.3 and ACM 8.4. These variants 
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occurred in the genes PARVA, ankyrin 3 Node Of Ranvier (ANK3), anaplastic lymphoma receptor 
tyrosine kinase (ALK), deleted in lung and esophageal cancer 1 (DLEC1), WW domain containing 
adapter with coiled-coil (WAC), HMGXB3, neuralized homolog (Drosophila)  (NEURL) and 
trichorhinophalangeal syndrome I (TRPS 1) while the homozygous variants were in the genes 
ubiquitin protein ligase E3 component N-recognin 4 (UBR4), SMAD family 5 (SMAD5), glutamate 
receptor ionotropic AMP3 (GRIA3) and zinc finger protein 141 (ZNF141). Of the five 
homozygous variants that were sequenced, four of the variants (ZNF141 g.331694-331695insC, 
SMAD5 g.135513085-135513086insC GRIA3 g.6586096-65866097insG and GRIA3 122336601-
122336602insG) were present in the unaffected sibling (ACM 8.9), and therefore did not 
segregate with disease, whereas the fifth variant (UBR4 c.15009_229-15009_228 insG) was 
detected at a frequency of 52% in the white population controls of South Africa thereby 
relegating its status to that of a single nucleotide polymorphism (SNP). All homozygous variants 
were also reported in the dbSNP database. Of the eight heterozygous variants, six were present 
in the unaffected sibling (and therefore did not segregate with disease).  Of the remaining two 
variants, (HMGBX3 c.607G>A and PARVA c.392A>T) the rare PARVA c.392A>T variant 
(frequency 0.007% as per Exome Variant Server (EVS)) was considered the most plausible 
candidate for ARVC in this family while the HMGXB3 c.607G>A variant was suggested to play a 
modifying role.    
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Table 2.1: Variants detected in two affected family members 
Gene Gene function DNA change 
Heterozygous variants   
Parvin, Alpha (PARVA) Plays a role in the organization of the actin cytoskeleton; 
and cell adhesion 
c.392A>T 
Ankyrin 3, Node Of Ranvier (ANK3) 
 
Maintenance of ion channels and cell adhesion c.2978C>T  
Anaplastic lymphoma receptor 
tyrosine kinase (ALK) 
Plays an important role in the genesis and differentiation 
of the nervous system 
 
c.4947G>A 
Deleted in lung and 
esophageal cancer 1 (DLEC1) 
Act as a tumor suppressor by inhibiting cell proliferation c.262C>G 
WW domain containing 
Adapter with coiled-coil 
(WAC) 
Regulates the cell-cycle checkpoint 
Activation in response to DNA damage 
c.1465A>G 
HMG box domain containing 3 
(HMGXB3) 
Plays a role in DNA replication and repair c.607G>A 
Neuralized homolog (Drosophila)  
(NEURL) 
May function as an E3 ubiquitin-protein ligase to activate 
monoubiquitination of JAG1 
c.563T>C 
Trichorhinophalangeal syndrome I 
(TRPS 1) 
Transcriptional repressor c.-9_-8insT 
Homozygous variants   
Ubiquitin protein ligase E3 
component N-recognin 4(UBR4) 
It regulates integrin-mediated signalling. c.15009_229-
15009_228inG 
SMAD family 5 (SMAD5) It functions as a transcriptional modulator activated by 
bone morphogenetic protein. 
c.1314_1316insC 
Glutamate receptor ionotropic 
AMP3(GRIA3) 
It functions as a glutamate receptor. c.382_383insG 
 Zinc finger protein 141 (ZNF141) It is involved in transcriptional regulation as a repressor g.331694-331695insC 
 
Mbele supported his hypothesis by describing the biological plausibility of the role of PARVA in 
cardiomyopathy as a cell adhesion protein, the rarity of PARVA mutations in the general 
 29 
 
population, evolutionary conservation of the amino acid change and the predicted deleterious 
effect on protein function.   
 Mbele then proceeded to screen 66 additional ARVC patients for mutations in PARVA and 
reported a pathogenic non-synonymous variant, c.523A>G (p.K156E), in one ARVC case and a 
synonymous variant of unknown significance, c.597T>G (p.T199) in another ARVC case.  
The PARVA gene encodes a PARVA protein which localizes to nascent focal adhesion sites which 
are sites of interaction between the cell and extracellular matrix (Nikolopoulos and Turner 
2000). The PARVA protein forms a ternary complex (PIP) through interactions with integrin 
linked kinase (ILK) and Particularly interesting new cysteine-histidine-rich protein (PINCH).This 
complex has been implicated in the control of signalling pathways through phosphorylation of 
downstream targets, mostly protein kinase B (PKB) and glycogensynthase kinase3 (GSK3 ). The 
complex also binds to upstream effectors of the Jun Nterminal kinase (JNK) signalling pathway 
and regulators of small molecular weight guanine triphosphatases (GTPases) for efficient cell-
extracellular matrix interactions for cell signalling (Legate, Montanez et al. 2006). PARVA also 
binds to a-actinin and Rho GTPase activating protein 31(CdGAP), which clarifies the prominent 
functions of PARVA in integrin-mediated cell adhesion and actin-dependent processes such as 
cell shape regulation and cell migration (Sopko, Qin et al. 2011) 
The PARVA protein encoded by the PARVA gene is 42kDa composed of 13 exons and the most 
distinct feature is the presence of two calponin homology (CH) domains in their C-terminal 
regions, named CH1 and CH2 (Sepulveda and Wu 2006) (Figure. 2.2).  
 
 
 
 
 
 
Figure 2.2: Structure of PARVA protein (Sepulveda & Wu, 2006) 
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Each CH domain is an area of actin-binding and comprises approximately 100 amino acids, 
separated by a 60-amino acid linker. The N-terminal with 95 amino acids is a major site of 
phosphorylation which confers conformational change to the whole protein and it has nuclear 
localization signals as well as src-homology 3 domain (SH3) binding sites of the consensus PXXP, 
where X is any amino acid but cysteine (Olski, Noegel et al. 2001). The CH2 domain contains 
paxillin binding site (PBS) that interacts with an integrin-linked kinase.  
For this project we continued to explore the role of PARVA as a candidate not only for ARVC but 
for other cardiomyopathy cohorts (DCM, HCM and RCM) as well. 
 
2.2. Aims 
The aims of this study were: 
1.) To screen for the PARVA c.392A>T variant in all members of the ACM8 family to 
determine segregation with disease. 
2.) To screen the cardiomyopathy cohorts (ARVC, DCM, HCM and RCM) consisting of 180 
probands for pathogenic PARVA variants. 
 
2.3. Methods 
2.3.1. ACM 8 Family 
All available family members of ACM 8 (ACM 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7,8.8 and 8.9) were 
enrolled in the ARVC Registry of South Africa which was established by the Working Group on 
Registries of the Cardiac Arrhythmia Society of Southern Africa (CASSA), as reported previously 
(Latib, Michaels et al. 2004). The registry is approved by the Human Research Ethics Committee 
of the Faculty of Health Sciences of the University of Cape Town (Appendix 1).  
The clinical phenotyping of this ACM8 family indicated that both affected children developed 
severe, early-onset ARVC with the proband presenting at 12 years and requiring a heart 
transplant at age 23 years. Unfortunately, the proband’s affected younger brother died at age 
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14 years. The proband’s mother, ACM8.2, had a later age of onset and displayed mild 
symptoms of ARVC. We have not phenotyped the father as he has not yet responded to 
invitations to visit Groote Schuur Hospital. 
 
2.3.2 Cardiomyopathy Cohort 
2.3.2.1 ARVC 
A diagnostic panel consisting of a group of cardiologists determined, by consensus, whether or 
not the referred cases met the diagnostic criteria for ARVC set by the Task Force of the Working 
Group on Myocardial and Pericardial Diseases of the European Society of Cardiology and of the 
Scientific Council on Cardiomyopathies of the International Society and Federation of 
Cardiology (McKenna, Thiene et al. 1994). The participants were classified as having definite 
ARVC (if Task Force criteria were met), probable or possible ARVC (if some criteria were met 
and no alternative diagnosis was found), or not having ARVC (if there was no evidence of ARVC 
and/or an alternative diagnosis was present). The diagnosis of ARVC in first-degree relatives of 
affected individuals was made based on the modified criteria of Hamid and colleagues (Hamid, 
Norman et al. 2002). For this investigation, 74 ARVC samples were screened. 
 
2.3.2.2 DCM 
DCM diagnosis was made on the basis of the definition of the European Society of Cardiology 
(Elliott et al. 2008). For this investigation, 68 DCM samples were screened. 
 
2.3.2.3 HCM 
HCM diagnosis was made on the basis of the definition of the European Society of Cardiology 
(Elliott et al. 2008). For this investigation, 28 HCM samples were screened. 
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2.3.2.4 RCM 
RCM diagnosis was made on the basis of the definition of the European Society of Cardiology 
(Elliott et al. 2008). For this investigation, 10 RCM samples were screened. 
2.3.3 Normal controls 
Controls were chosen from healthy, anonymous blood donors with no history of heart disease 
from the Western Province Blood Transfusion Service (WPBTS) provided blood samples for DNA 
isolation. The 232 anonymous blood donors were from 99 people of mixed ancestry, 62 black 
Africans, 11 people of Indian origin and 60 white South Africans. Informed consent was 
obtained from all participants (Appendix 3).  
  
2.3.4. DNA extraction 
Peripheral blood samples were collected from participants in 5 ml ethylenediaminetetraacetic 
acid (EDTA) tubes. The genomic DNA (gDNA) was extracted from peripheral blood using the 
PureGene™ DNA isolation kit (Gentra system, USA) and was extracted according to the 
manufacturer’s instructions (Appendix 4). The gDNA samples were given disease code numbers 
(ACM to refer to the disease ARVC) to anonymize them and were filed in the database of the 
Cardiovascular Genetics Laboratory at the Hatter Institute for Cardiovascular Research in Africa, 
Department of Medicine, University of Cape Town. Extracted DNA samples were stored at -80°C 
for long term storage.   
 
2.3.5. DNA quality control 
2.3.5.1 Nanodrop quantification 
All the DNA samples were mixed prior to measurement and were quantified at an absorbance 
of 260 nm using a NanoDrop ND-2000 spectrophotometer (ThermoScientific, UK).  Each sample 
was measured twice for confirmation of its concentration, and the average of the two 
measurements was taken as the concentration of each sample.  All primary DNA extractions 
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were also validated using the Qubit™ Fluorometer (Invitrogen, USA) which is considered an 
accurate determinant of nucleic acid concentrations.  
 
2.3.5.2 Gels 
The DNA samples were electrophoresed on an agarose gel to confirm the presence of good 
quality DNA.  
Agarose is composed of repeated agarobiose (L- and D-galactose) subunits whose polymers 
form a non-covalent association and to give a network of bundles with pore sizes that 
determine a gel's molecular sieving properties. For the DNA separation in agarose gel 
electrophoresis, the DNA is loaded into pre-cast wells in the gel and a current applied. The DNA 
phosphate backbone is negatively charged, thus when placed in an electric field, DNA 
fragments migrate to the positively charged anode. Because DNA has a uniform mass/charge 
ratio DNA molecules are separated by size within the agarose gel in a pattern such that its 
molecular weight is inversely proportional to the distance it traveled (Lee, Costumbrado et al. 
2012).  
 
The migrated DNA in the gel was stained by GelRedTM (Biotium, US), a fluorescent nucleic acid 
stain, for visualization of the DNA. GelRedTM intercalates between the base pairs of the DNA 
strands and is visualized under ultraviolet (UV) light. The loading of the DNA and the monitoring 
of electrophoretic progression were assisted with the electrophoresis buffer, 3μl of 1X loading 
dye with a DNA ladder (New England BiolabsR 100bp DNA ladder)  (Appendix 2). The DNA ladder 
was run alongside extracted samples to give the sizes of the samples electrophoresed through a 
1.5% agarose gel in 1X TBE buffer at 120 V for 90 minutes. 
 
All gDNA samples were divided into long term stock solutions which were stored in a -80°C 
freezer. For experimental purposes, working stocks of DNA were standardized to 50ng/µl and 
stored at 4°C. 
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2.3.6 Polymerase Chain Reaction  
DNA fragments of interest are amplified by means of the polymerase chain reaction (PCR) prior 
to HRM in the presence of a third generation intercalating dye called EvagreenTM (Biotium, US). 
 
2.3.6.1. The principle of PCR 
PCR is a molecular technique that makes it possible to amplify specific DNA regions.  Under 
specific temperature cycling conditions, primers, which are two complementary oligonucleotide 
sequences that flank the DNA segment of interest, direct the specific amplification of the target 
DNA fragment making use of Taq polymerase and deoxynucleotide triphosphates (dNTPs).  
With each cycle, the concentration of target DNA doubles resulting in generation of multiple 
target sequence copies to be used in downstream applications (Garrett et al. 2005). 
 
Sample DNA was amplified using real-time PCR in this project which makes it possible to 
amplify and quantify a DNA sequence simultaneously. This PCR was done in the presence of an 
EvaGreenTM (Biotium) dye which interacts and intercalates with only double stranded DNA thus 
fluorescing when bound. A shift in the fluorescence of the solution occurs due to an increase in 
the amount of DNA in the solution as PCR progresses and this fluorescence can be used to 
measure DNA concentration at different times during the reaction.  
 
2.3.6.2. Gene annotation and primer design 
Primers were designed to amplify all coding regions of PARVA. The PARVA gene was annotated 
using the AnnotV9 annotation programme using PARVA genetic sequence which was 
downloaded from Ensembl, GRCh38 (Yates, Akanni et al. 2016) (http://www.ensembl.org, 
accession number ENSG00000197702, transcript ENST00000334956) (Rebello, 2006; 
unpublished methodology). Primer sequences were chosen manually by referring to the 
annotated variants gene sequence, and analyzing the chosen sequences using IDT 
OligoAnanlyzer (http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/Default.aspx) 
and NCBI BLAST (Boratyn, Camacho et al. 2013) (http://blast.ncbi.nlm.nih.gov/Blast.cgi) web-
based tools for the determination of the optimal primer sequences for the gene amplification.     
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The primers were required to have:- 
 (1)  A length of between 18 and 25 base pairs 
 (2)  Good sequence diversity with minimal sequence repeats and secondary structure 
 (3) A melting temperature of between 50°C and 60°C 
 (4) A GC content of between 45% and 65%, and  
 (5) A G or C clamp at the 3’ end.  
An increase in amplicon size in HRM leads to a subsequent decrease in resolution of both the 
amplicon being screened and thus any mutation that is to be detected. Because of this, the 
amplicon sequence lengths were restricted to 250-300 bp in length. Using these criteria primer 
sets were designed for the combined PCR and HRM amplification and analysis of the PARVA 
exons and synthesized by Integrated DNA Technologies (IDT) (IDT, US)  (Table 2.2).  
The primer pairs used for the HRM analysis of the PARVA exons are as shown in Table 2.2 
below. 
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Table 2.2: Primer pairs used for HRM analysis of PARVA exons 
Primer PCR products size (bps) Sequence (5’-3’) Annealing Temperature (
o
C)  
1-1F 246 AAG GGA AAG GCG AGC GTG 55 
1-1R AAT CAT CTT TCT TGC GGG ACG GG 
1-2F 410 AAA GCC GCA GCC TCA GTC 55 
 1-2R CTC AGT GTG GGG TGC GCG TCG 
2F 206 TGTTACAGAGCTCCAACCCC 55 
2R GCTGGCATGGGAAAGCTTAA 
3F 327 CCA TCA ACC TGC CCC TCA G 55 
3R GCT GCC ATG ACT TTT TAC CTT CTC 
4F 205 GCTGGTCTGTAAGAAAATACCCC 55 
4R CACACATCCATTGCAGCACT 
5F 285 GCATGCAGTAGGGTTGTCTG 55 
5R ATGGATGGCTTCTTGGGGAA 
6F 248 TGCCTAGAACCTGGAAGAAGA 55 
6R  GACCTACTCGACGCACCATA 
7F 187 CAGGAATGCTCATCAGTGTTTC 55 
7R TCCCTCCTGCAATCCCAATA 
8F 194 GCA GTG ATG GAG TGT CCT TTC 55 
8R TGA GAG CCT GTT CCT CCC AG 
9F 241 GAGGCTTCCCATCGGTAGTT 55 
9R TCCCAATGTTCTGTTGCATCTC 
10F 327 TTT CAC CCT CAC CCT TGC CCT C 55 
10R TCC ACA GAG ACT CAG TCC ACC 
11F 227 GGTAGGCTTCAGGTGGCATA 55 
11R TCCCTTGATGTCCCTTCTCC 
12F 244 TGCTGGGCTCCTTCACTTC 55 
12R TGCTTCCCTCTGCTACAAAATC 
13F 258 GAA GGG AGG GGC AGT GTA TG 55 
13R CAC AGT GCA AGA GAC AGG 
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2.3.7. HRM analysis 
HRM analysis is used to detect any potential mutations in samples analyzed in comparison to 
control samples.  
2.3.7.1 The principle of HRM Analysis 
Detection of mutation by HRM analysis is a two-step process involving amplification of the 
target DNA sequence using PCR and analysis of the produced amplicon by HRM.  With the 
RotorGene 6000 (Corbett Life Sciences, Australia), these two steps can be combined into a 
single procedure where DNA samples are amplified and then immediately subjected to HRM. 
HRM analysis is based on the dissociation behavior of double stranded DNA (dsDNA) dsDNA 
due to increasing temperature. Melting of dsDNA depends on its GC content and overall 
distribution of bases. 
In HRM analysis, investigation of the melting curve can distinguish between several PCR 
amplicons with subtle changes in sequence and length, down to the single nucleotide level 
(Figure 2.3). 
 
 
 
Figure 2.3:  Melt curve showing the high efficiency of HRM to single base nucleotide 
 
During HRM, the PCR amplicon is exposed to increasing temperature. The fluorescence of third-
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increasing temperature. At lower temperatures, all DNA is double-stranded thus fluorescence is 
high. The DNA will start to disassociate into two single strands as the temperature increases, 
resulting in DNA melting. At this point, the dye is released and the fluorescence will decrease. 
The melting temperature (Tm) of the DNA sample under analysis is the point of the melt phase 
where the rate of change in fluorescence is greatest. When the DNA is completely melted, only 
some background fluorescence will be detected. 
DNA strands of a PCR product are bound together by hydrogen bonds and additional 
interactions such as base stacking forces. Depending on the strength of these interactions and 
different parameters surrounding a particular PCR amplicon such as the length of the amplicon, 
the overall base composition, and the local GC content within the PCR amplicon, each amplicon 
will have a differential melting behavior thus deliver a characteristic melting profile (Figure 2.4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Melt curve profiles of different PCR amplicons each with differential melt curves (URL15) 
 
 
2.3.7.2 HRM Protocol 
The reagents used for the combined real-time PCR and HRM of the variant amplicons are 
shown in Table 2.3 and the reaction conditions are shown in Table 2.4. Scientific Specialities Inc 
Kits (ssibio, US) were used for HRM analysis. 
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Table 2.3: Reagents and concentrations in PCR and HRM of the variants exons  
REAGENT (STOCK CONCENTRATION) FINAL CONCENTRATION (µM) OR VOLUME IN 
SOLUTION QUANTITY (μl) 
Forward primer (20μM) 0.4 
Reverse primer (20μM) 0.4 
dNTPS (20uM) 0.8 
GoTaq Polymerase (5U/μl) 0.5U 
MgCl2 (25mM) 3 
Evagreen (20x) 0.5 
DNA 50ng 
dH2O 13.4 
Total 25 
 
 
Table 2.4: Optimized temperature cycling conditions for the PCR and HRM of the variant exons 
CONDITION TEMPERATURE (TIME) 
Initial denaturation 95°C - 10 minutes 
Denaturation 
Primer Annealing 
                                95°C – 5 seconds  
                                95°C - 10 seconds    50 cycles 
Temperature Elongation 72°C - 10 seconds 
High Resolution Melt 72-95°C 
(0.1°C increments) 
 
2.3.7.3 Purification of HRM products 
After HRM analysis, the samples identified for sequence analysis were purified using the 
Thermosensitive Alkaline Phosphatase (Applied Biosystems, US) and Exonuclease I (Applied 
Biosystems) enzymes. The reagents used are shown in Table 2.5. Reactions were incubated at 
37°C for 1 hour, after which a 75°C deactivation step was conducted for 15 mins in a MultiGene 
Gradient thermal cycler (Labnet International). 
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Table 2.5: Cleanup protocol for variant HRM products 
REAGENT FINAL CONCENTRATION (µM) OR VOLUME IN 
SOLUTION QUANTITY (μl) 
Exonuclease I (20U/μL) 2U 
Thermosensitive Alkaline Phosphatase (1U/uL) 1U 
Distilled/deionized water  13.9 
HRM product 5 
Final reaction volume 20 
 
2.3.8 Sanger sequencing 
Sanger sequencing was performed on all samples that showed a variation in the melt profile 
compared to the controls. 
2.3.8.1. The principle of Sanger sequencing 
Sequencing makes it possible to elucidate the alignment of base pairs in a DNA molecule. To 
carry out the procedure, the DNA of interest is mixed with DNA polymerase, deoxynucleotide 
triphosphates (dNTPs), four labelled dideoxynucleotide triphosphates (ddNTPs) and a 
sequence-specific oligonucleotide primer. DdNTPs and dNTPs are incorporated into the growing 
strand in a similar manner to each other, but the incorporation of the ddNTPs causes strand 
termination.  For the sequencing reaction, temperature cycling similar to PCR is employed 
(Hartwell et al. 2004). 
 
The sequencing reaction will generate a complete series of small fragments, each ending with a 
fluorescently labelled ddNTP. The small fragments can be separated by capillary electrophoresis 
and detection of the different ddNTPs will allow the DNA sequence of this strand to be 
determined (Luckey and Smith 1993). 
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2.3.8.2 Sequencing of variant exons 
Sequencing of the HRM products was performed using the BigDye® Terminator v3.1 Sequencing 
Kit (Applied Biosystems). The reagents used for the direct sequencing reaction of the variants 
are described in Table 2.6.  The temperature cycling conditions were conducted in a MultiGene 
Gradient thermal cycler (Labnet International) and the sequencing reactions are as described in 
Table 2.7. 
 
Table 2.6: PCR protocol for the sequencing reactions of variant amplicons 
REAGENT FINAL CONCENTRATION (µM) OR VOLUME IN 
SOLUTION 
Forward Primer (1 µM) 0.1 
BigDye ® Terminator v3.1. Ready Reaction Mix       
(Applied Biosystems) 
2 μl 
5 X Sequencing Buffer (Applied Biosystems) 1 
Distilled/deionized water 9 μl 
HRM product 3 μl 
FINAL REACTION VOLUME 20 µl 
 
Table 2.7: Optimised cycling conditions for the sequencing reactions of variant amplicons 
CONDITION          TEMPERATURE (TIME) 
Initial denaturation                     96°C - 5 minutes 
Denaturation 
Primer Annealing 
Template Elongation 
                    96°C - 30 seconds 
                    50°C - 15 seconds       25 cycles 
                    60°C - 4 minutes 
2.3.8.3 Capillary electrophoresis 
Analysis of the sequencing products was done using capillary electrophoresis at the DNA 
Sequencing Unit (Department of Genetics, Stellenbosch University), by means of an ABI PRISM® 
3130xl Genetic Analyzer (Applied Biosystems) or an ABI PRISM® 3730xl Genetic Analyzer 
(Applied Biosystems). 
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2.3.9 Bioinformatic Tools/ Public Genome Browsers/Databases 
The pathogenicity of variants was determined using the three gene prediction tools 
MutationTaster (Schwarz, Cooper et al. 2014) (http://www.mutationtaster.org/), SIFT (Nelson, 
Stucker et al. 2016) (http://sift.jcvi.org/) and PolyPhen-2 (Adzhubei, Schmidt et al. 2010) 
(http://genetics.bwh.harvard.edu/pph2/) (Appendix 5).  
 
2.4. Results 
2.4.1. ACM 8 family screen 
The PARVA c.392A>T variant, identified by Mbele in 2014, was screened in all ACM8 family 
members in order to confirm its segregation within all members of the ACM8 family. HRM 
variant analysis of the c.392A>T variant in the family indicated a deviation in HRM profiles 
between the wildtype and ACM 8.2, 8.3, 8.4 (Figure 2.5 A and B). Sequencing results for the 
family were compared to a control (Figure 2.5 C and D). 
 
  A                   B 
                
 Figure 2.5: Validation of the PARVA c.392A>T Exon 3 variant. The black arrow (C-D) points to the 
region of interest. (A) and (B) HRM graph showing the exon 3 melting curve and peak graphs of 
sample ACM8.3 (black line) against a negative control (red line); 
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   C                               D           
                                
Figure 2.5: Validation of the PARVA c.392A>T Exon 3 variant. (C) Sequencing electropherogram showing 
the PARVA sequence in a control sample in the region of interest; (D) Sequencing electropherogram 
showing the c.392A>T sequence change in ACM 8.3 
The c.392A>T variant was only found in the confirmed affected family members, ACM8.2, 8.3 
and 8.4 and its segregation pattern is as shown in the pedigree chart below (Figure 2.6). 
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Figure 2.6: Pedigree chart for ACM 8 family showing the segregation of the PARVA c.392A>T 
 
 44 
 
2.4.2. Cardiomyopathy cohort screen 
Through HRM analysis and Sanger sequencing we screened PARVA for pathogenic variations in 
our cardiomyopathy cohorts (ARVC, DCM, PCM and RCM) consisting of 180 probands. We 
observed three reported single nucleotide polymorphisms (SNPs) (Table 2.8). 
Table 2.8: Results of PARVA screening in a cardiomyopathy cohort 
 
2.4.3 Variant functional analysis 
Of the variants analyzed, only PARVA c.392A>T was predicted to be deleterious by all of the 
three prediction tools as shown in Table 2.9 below. The other variants were synonymous and 
intronic and were therefore unlikely to affect protein function. 
Table 2.9: Variants identified in PARVA 
 
 
Variant Location Frequency in 
Cardiomyopathy 
cohort (%) 
Frequency in 1000 
Genomes population 
(%) 
rs number 
c.726C>T p.R242 Exonic 1.5 14 11547363 
c.777+10G>A Intronic 0.9 3 111731473 
c.777+26C>G Intronic 0.9 2 74401006 
Variant Location MutationTaster Sift Polyphen 
c.392A>T p.D131V Exonic Disease causing (0.999) Damaging (0.01) Probably damaging (0.990) 
c.726C>T p.R242 Exonic Polymorphism (1.246) Tolerated (1) N/A 
c.777+10G>A Intronic N/A N/A N/A 
c.777+26C>G Intronic N/A N/A N/A 
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2.4.4 Population screening 
We screened the PARVA c.392A>T variant in order to determine the frequency in the South 
African background population (Table 2.10). The PARVA c.392A>T variant was previously 
investigated in our research group and reported to be absent in the South African control 
population (Mbele, 2014) as well as the 1000 Genomes Project database. It was however found 
in Exome Aggregation Consortium browser (ExAC) (Lek, Karczewski et al. 2016) and EVS but was 
considered to be rare according to the frequencies observed in the databases mentioned.  
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Table 2.10: Population frequencies of the PARVA c.392A>T variant 
Locus Gene Coding Amino Acid 
change 
Frequency in 
SA 
population 
(%) 
Frequency in 
EXAC (%) 
Frequency 
in 1000 
Genomes 
(%) 
Frequency in EVS 
(%) 
chr11:12495505 
 
PARVA 
 
c.392A>T 
 
p.Asp131Val 
 
0/60 (0%)  1/32962 
(0.03%) 
0 (0%) 1/12227 
(0.08%) 
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2.5. Discussion 
At the outset of this investigation we wanted to establish the causal role of PARVA in ARVC 
based on previous experiments done by Dr.Mbele that identified it as a possible candidate gene 
for ARVC.  
PARVA has many functional roles that make it a biologically plausible candidate not just for 
ARVC but for cardiomyopathy as well. This gene (1) forms an integral component of cell 
adhesion complexes (Nikolopoulos and Turner 2000), (2) has a role in reorganization of the 
actin cytoskeleton, sarcomere organization, smooth muscle cell contraction, etc. (Wang, 
Fukuda et al. 2008) and (3) is highly expressed in the heart (Sopko, Qin et al. 2011) . 
Experiments in mice have shown that mice deficient of Parva express cardiovascular defects in 
the embryonic stage which includes abnormal vascular beds with dilated blood vessels and 
pericardial effusion combined with whole body edema and severe bleeding due to vessel 
rupture (Montanez, Wickstrom et al. 2009). Sopko et.al utilized failing DCM human heart 
tissues, and found a 2.27-fold enhanced expression of PINCH, while the expression of PARVA 
and ILK were similarly increased 4- and 10.5-fold, respectively (Sopko, Qin et al. 2011). These 
findings led them to purport the improvement of cardiac function by enhancing PIP mediated 
Protein kinase B (Akt) activation (Sopko, Qin et al. 2011). In human cardiac myocyte the ternary 
complex is localized in the costameres which overlap the Z-line of cardiac myocytes and play a 
role in myocyte hypertrophy through sarcomere assembly (Chen, Huang et al. 2005).  
For my project we continued to screen the ACM 8 family for the PARVA c.392A>T variant to 
determine the segregation with disease and found the variant to occur in both severely 
affected siblings (ACM 8.3 and ACM 8.4) as well as the mildly affected mother (ACM 8.2). The 
differences in phenotype amongst the ACM 8 family members may be due to the incomplete 
penetrance of ARVC or a possible genetic modifier such as HMGXB3. Incomplete penetrance 
arises in the case where individuals harbouring identical mutations show differing phenotypes, 
and such variation can sometimes be due to different genetic backgrounds or even 
environmental conditions (Raj, Rifkin et al. 2010).  This phenotypic variability in ACM 8 cannot 
be explained by the PARVA c.392A>T variant and called into question the causative role of 
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PARVA within this family. We also screened our cardiomyopathy cohorts consisting of 180 
probands (ACM, DCM, DCM and RCM) for PARVA mutations but only common SNPs were 
identified.   
In the initial study in 2012, Dr Mbele had screened 66 additional ARVC patients for mutations in 
PARVA and reported a novel pathogenic non-synonymous c.523A>G variant in one ARVC case 
(ACM 30.1) and a synonymous variant of unknown significance, c.597T>G in another ARVC case 
(ACM 32.1). Further investigation of these patients by the cardiomyopathy panel revealed that 
both probands do not meet the criteria for ARVC even though they had initially been diagnosed 
with ARVC.  The panel found that ACM 30.1, initially classified as having ARVC based on the 
presence of an arrhythmia with a left bundle branch block morphology and a superior axis, has 
no other criteria for ARVC; he has a hypertensive heart disease and previous myocardial 
infarction (S Kraus, personal communication).  They also found that ACM 32.1 has an 
unclassified cardiomyopathy affecting the left ventricle with ventricular tachycardia (with right 
bundle branch block morphology) but does not fulfil any criteria for ARVC according to Task 
Force Criteria. These findings by the panel on the phenotype of these two probands now casts 
doubt on the role of PARVA in cardiomyopathy as both probands do not have a definitive 
diagnosis aside from the mentioned ventricular tachycardia.  
In summary, Dr Mbele had identified three PARVA variants (c.392A>T; c.523A>G; c.597T>G) in 
patients with ARVC but we consider these variants to be disease-associated rather than 
definitely pathogenic for several reasons. Firstly, the PARVA c.392A>T variant cannot explain 
the variation in phenotype that is seen in the ACM 8 family. Secondly, the other two variants 
were classified as variants of unknown significance as the patients’ diagnosis was unclear and 
we were ambiguous of the role that PARVA played in these two patients. We could not 
comment on familial segregation as the families were not available for phenotyping. We classify 
these three variants as ARVC-associated but not definitely pathogenic. 
In this small study, our observations do not provide strong supporting evidence for PARVA as a 
candidate gene for ARVC or any other cardiomyopathy.   
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Chapter 3: WHOLE EXOME SEQUENCING OF ACM 8 
3.1. Introduction 
We elected to validate Dr.Mbele’s findings in the South African setting by using the Ion Torrent 
platform and compare the results to the Illumina platform that had been used by Mbele in the 
UK.  The successful validation of his results would achieve several goals: (1) it would verify that 
the next generation sequencing (NGS) techniques had been appropriately set up in our 
laboratory (2) that we had acquired the skills necessary for data analysis of NGS data (3) 
reproducing the data from the UK whole exome sequencing experiment would allow us to 
examine the data for other possible causative variants.  
Whole genome sequencing and whole exome sequencing (Berglund, Kiialainen et al. 2011) form 
the new wave of next generation sequencing (NGS)  technologies that have enabled the 
identification of novel genes responsible for disease phenotypes (Mardis 2013). We explored 
whole exome sequencing technologies as an improvement to the laborious yet fundamental 
Sanger sequencing method of DNA sequencing (Sanger, Nicklen et al. 1977);  this has enabled 
the accelerated study of DNA on a genome-wide scale thus improving the nature of biological 
inquiry (Mardis 2013).. NGS has therefore become an invaluable tool in the elucidation of the 
genetics of cardiomyopathy, where much of the genetic influence on the disease remains to be 
discovered.  
 
3.2 Aim 
The aim of this investigation was to validate the whole exome sequencing findings carried out 
on an Illumina platform in the UK on an Ion Torrent platform in South Africa.  
 
 50 
 
3.3 Methods 
3.3.1 Sample library preparation 
The human genomic DNA (gDNA) samples of ACM 8.3 and ACM 8.4 were submitted to the 
Centre for Proteomic and Genomic Research (CPGR) for whole exome sequencing on the Ion 
Proton sequencer. 
These samples were first analyzed on the NanoDrop ND1000 (Thermo Fisher Scientific) to 
assess sample purity and quality, the Qubit®2.0 Fluorometer for absolute quantification and 
finally on a 1% agarose gel to assess integrity of the high molecular weight gDNA. 
A total of 100 ng of each sample was used as template in the exome amplification PCR protocol 
using the Ion AmpliSeq™ Exome RDY Kit (Life Technologies, US). The amplicons were treated 
with the FuPa Reagent (Life Technologies) to partially digest the primers and phosphorylate the 
3'-ends thus ensuring efficient ligation reactions downstream. Amplification products were 
ligated to lon Xpress™ Barcode Adapters (Life Technologies) and purified using Agencourt 
Ampure XP beads (Beckmann Coulter, US). Amplification products with ligated adaptors were 
then amplified through a limited cycle PCR, and purified with Agencourt Ampure XP beads 
(Beckmann Coulter). The barcoded amplification products (sequencing libraries) were then 
quantified by quantitative PCR (qPCR) using the KAPA Library Quantification kit for Ion Torrent 
(KAPA BioSystems, SA) and fragment size distribution was determined on the BioAnalyzer 
instrument using the BioAnalyzer High Sensitivity DNA Assay Kit (Agilent, US). 
Libraries were diluted to 40pM for templating on the Ion Chef instrument (Life Technologies) 
using the Ion PI™ Hi-Q™ Chef Kit and Ion PI™ Chip Kit v3 (Life Technologies).  Sequencing was 
carried on the Ion Proton™ System using the Ion PI™ HiQ™ Sequencing 200 Kit (Life 
Technologies). 
 
3.3.2 Library quality control 
Absolute library concentration and fragment size distribution are key quality control (QC) 
results post library preparation and prior to sequencing. The library concentrations were 
determined by qPCR.  The fragment size distribution analysis was performed on the Bioanalyzer 
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(Agilent) using the BioAnalyzer High sensitivity DNA Assay kit (Agilent). The Ion AmpliSeq™ 
Exome RDY library (Ion Torrent) preparation method ideally yields library fragments with a size 
distributed between 200 and 350 bp. 
 
3.3.3 Data Analysis 
A summary of the sequencing data output including the number of reads and quality of data 
was produced per sequencing run.   
 
The two samples were multiplexed per chip and the QC metrics were generated using Torrent 
Suite v4.4.3. Overall, the number of reads per sample ranged from ~20 – 55 million. Results of 
the secondary on-board analysis on Torrent Suite shows a categorization of total data per run 
following alignment recalibration against the GRCh37.p5 reference from Phred 17, 20 and 
above (AQ17, AQ20 and “Perfect” corresponds to corresponds to <1% error rate).  
Overall, alignment against the GRCh37.p5 (hg19) reference was at least 96% indicating a 
maximum of 4% unaligned data down to AQ17; thus a minimum of 98% mean raw accuracy 
 
Raw data from the CPGR were uploaded to IonReporterTM. The data were initially processed on 
IonReporterTM before being downloaded and filtered.  
 
3.3.4 Variant filtering 
A list of 189 known cardiomyopathy-associated genes, generated from the NGS panel (n=48 
genes (GENETestsTM ©2016)), PAN cardiomyopathy panel (n=103 genes (Blueprint Genetics © 
2016)) and elife (n=159 genes (Zou, Tran et al. 2015)), was used for initial filtering of the whole 
exome sequencing data. For variants occurring in the gene panel, we looked for variants 
occurring in both affected siblings and applied the following filters: (1) variants with a minor 
allele frequency (MAF) of <1% according to IonReporterTM (2) variants occurring within exons or 
spanning intron/exon boundaries (3) all variants that occur as missense, nonsense, stop/loss 
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and insertions and deletions. All variants were validated using Sanger sequencing and in 
appropriate population controls to determine the frequency in the population. 
 
3.3.5 Bioinformatic Tools/ Public Genome Browsers/Databases 
The pathogenicity of all non-synonymous rare variants was determined as described previously 
(Section 2.3.9). Only variants predicted to be disease causing by at least two out of the three 
prediction tools were considered for further analysis. To check for the expression levels of 
these gene transcripts in the heart, a human gene online database, GeneCards 
(http://www.genecards.org/) (Stelzer, Plaschkes et al. 2016), was used.  
 
3.3.6. Validation of potentially disease-causing variants 
The validation of shortlisted variants was done using PCR and HRM analysis (Sections 2.3.6 and 
2.3.7) followed by Sanger sequencing (Section 2.3.8) using the primers described in Table 3.1. 
All available ACM 8 family members were screened for the shortlisted variants in order to 
determine segregation of these variants with disease. 
 
Table 3.1: Primer set for HRM analysis of c.1162C>T variant in ACM 8 family 
Primer PCR products size (bps) Sequence (5’-3’) Annealing Temperature (
o
C)
  
Variant 
4F 291 AGT ATT CGC TGA GTC GTC TCT 55 c.1162C>T 
4R GCA AAG TCA CCA TAA TAG AAG  
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3.4. Results 
3.4.1. Variant filtering for the known cardiac genes 
Using the Ion AmpliSeqTM Exome RDY Kit, a total of 30,500 shared variants were identified 
between ACM 8.3 and 8.4 at an average sequencing depth of 125X.  
We looked for variants occurring in both affected siblings and applied the following filters: (1) 
variants with a minor allele frequency (MAF) of <1% according to IonReporterTM, (2) variants 
occurring within exons or spanning intron/exon boundaries, (3) all variants that occur as 
missense, nonsense, stop/loss and insertions and deletions. All variants were validated using 
Sanger sequencing and in appropriate population controls to determine the frequency in the 
population (as per “Methods” section 3.3.4). 
Filtering for variants appearing in the cardiac gene panel resulted in us mining 232 common 
variants (Figure 3.1). These variants were subjected to further filtering which allowed us to 
decrease the total number of variants to 17: nine mutations were homozygous (Table 3.2) and 
eight were heterozygous variants (Table 3.3).  One variant however, PKP2 c.1162C>T, stood 
clearly above the rest as this variant has previously been reported to be associated with ARVC 
by our group (Watkins, Hendricks et al. 2009). 
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Figure 3.1: Filtering of whole exome sequencing data 
Figure 3.1: Filtering of whole exome sequencing data by using the known cardiac genes as a filter. 
30500 
12456 
232 
17 
9 
1 
Total variants shared between the two individuals 
Exonic single nucleotide variants (SNV), in/dels shared between 
the two 
Cardiac variants shared 
Cardiac variants shared with a MAF < than or equal to 0 
Homozygous cardiac variants shared 
Known disease-causing mutation in ARVC 
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Table 3.2: Results of variant filtering in the homozygous cardiac gene variants 
Locus Genes Coding Amino Acid 
Change 
Mutationtaster Sift Polyphen  Expression in the 
heart (Log10 ppm) 
chr12:33021869 
 
PKP2 (Akinrinade, Ollila et 
al. 2015) 
 
c.1162C>T 
 
p.Arg388Trp 
 
Polymorphism (0.999) Damaging 0 Probably damaging 
(0.999) 
251 
 
chr2:179444768 TTN (Akinrinade, Ollila et 
al. 2015) 
c.62323G>C p.Ala20775Pro Polymorphism (0.999) Not predicted Benign (0.000) 1056 
chr1:228444565 OBSCN (Zou, Tran et al. 
2015) 
c.4799T>A p.Val1600Asp Polymorphism (0.999) Tolerated 1  20 
chr10:29822032 
 
SVIL (Zou, Tran et al. 2015) c.1264G>A 
 
p.Val422Ile 
 
Polymorphism (1) Not scored Benign (0.000) 
 
3 
 
chr6:152540278 
 
SYNE (Akinrinade, Ollila et 
al. 2015) 
c.21904T>G 
 
p.Phe7302Val 
 
Polymorphism (0.999) 
 
Tolerated 0.55 Benign (0.000) 
 
0.7 
 
chr10:112572458 
 
RBM20 (Akinrinade, Ollila 
et al. 2015) 
 
c.2303G>C 
 
p.Trp768Ser 
 
Polymorphism (0.999) 
 
Tolerated 0.85 Benign (0.000) 
 
0.6 
 
chr12:2791205 
 
CACNA1C (Zou, Tran et al. 
2015) 
c.5678A>G 
 
p.Lys1893Arg 
 
Polymorphism (0.999) 
 
Tolerated 0.88 Benign (0.000) 
 
0.54 
 
chr7:91714911 
 
AKAP9 (Zou, Tran et al. 
2015) 
 
c.8935C>T 
 
p.Pro2979Ser 
 
Polymorphism (0.999) 
 
Tolerated 1 Benign (0.000) 
 
0.09 
 
chr3:38739574 
 
SCN10A (Zou, Tran et al. 
2015) 
c.5137A>G 
 
p.Met1713Val 
 
Polymorphism (0.999) 
 
Tolerated 1 Benign (0.000) 
 
0 
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Table 3.3: Results of variant filtering in the heterozygous cardiac gene variants 
Locus Genes Coding Amino Acid Change Mutationtaster Sift Polyphen  Expression in the 
heart (Log10 ppm) 
chr10:29821758 
 
SVIL (Deo, Musso et al. 
2014) 
 
c.1538G>A 
 
p.Ser513Asn 
 
Polymorphism (0.73) 
 
Not scored Benign (0.004) 3 
chr1:144854581 
 
PDE4DIP (Zou, Tran et 
al. 2015) 
c.6889A>G 
 
p.Thr2297Ala 
 
Polymorphism 0.99 
 
Tolerated 0.74 Benign 0.000 
 
2 
chr1:144871755 
 
PDE4DIP (Zou, Tran et 
al. 2015) 
c.5207T>A 
 
p.Val1736Glu 
 
Polymorphism 0.99 
 
Tolerated 0.32 Benign 0.361 
 
2 
chr1:144871782 
 
PDE4DIP (Zou, Tran et 
al. 2015)  
c.5180T>C 
 
p.Leu1727Pro 
 
Disease causing 0.83 Tolerated 1 Benign 0.000 
 
2 
 
chr1:144874815 
 
PDE4DIP (Zou, Tran et 
al. 2015) 
c.4793A>G 
 
p.His1598Arg 
 
Polymorphism 0.99 
 
Tolerated 0.15 Benign 0.001 2 
 
chr1:144879054 
 
PDE4DIP (Zou, Tran et 
al. 2015) 
c.4396A>G 
 
p.Arg1466Gly 
 
Polymorphism 0.99 
 
Tolerated 0.22 Possibly damaging 
(0.835) 
 
2 
 
chr15:99646108 
 
SYNM (Zou, Tran et al. 
2015) 
 
c.703A>G 
 
p.Arg235Gly 
 
Polymorphism 0.99 Not scored Benign 0.001 34 
chr22:19929263 
 
COMT (Zou, Tran et al. 
2015) 
c.64G>A 
 
p.Val22Met 
 
Polymorphism 0.99 
 
Tolerated 0.24 
 
Benign 0.261 21 
 
 57 
 
3.4.2 Identification of the PKP2 c.1162C>T founder mutation  
Through the abovementioned filtering criteria we identified the homozygous PKP2 c.1162C>T 
mutation in the two affected individuals, ACM 8.3 and ACM 8.4 (Table 3.2). This mutation was 
verified by HRM analysis (Figure 3.2 A and B) and Sanger sequencing (Figure 3.2 C-E). 
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Figure 3.2: Identification of the PKP2 c.1162 C>T mutation in exon 4 of the affected siblings of the 
ACM 8 family. HRM showing the exon 4 derivative melt profiles of sample (A) the proband (ACM8.3) 
and a negative control and (B) the sibling  (ACM 8.4) and a negative control; Sequencing 
electropherogram of the (C) the proband (ACM 8.3),  (D) the sibling (ACM 8.4)  and (E) the control 
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3.4.3 Segregation of the PKP2 c.1162C>T founder mutation  
The founder mutation was further screened by HRM analysis and Sanger sequencing in seven 
other family members, ACM 8.1, 8.2, 8.5, 8.6, 8.7, 8.8 and 8.9 (Figures 3.3 and 3.4). The father 
(ACM 8.1) and the mother (ACM 8.2) were confirmed to carry the PKP2 c.1162C>T mutation 
respectively (Figure 3.3). These results confirm that the siblings (ACM 8.3 and ACM 8.4) had 
inherited a mutant copy from each parent, resulting in the homozygous genotype (Figure 3.5).  
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Figure 3.3: Identification of the PKP2 c.1162 C>T mutation in exon 4 of the parents of the ACM 8 family.  HRM 
showing the exon 4 derivative melt profiles of sample (A) the father (ACM 8.1) and a negative control and (B) 
the mother  (ACM 8.2) and a negative control; Sequencing electropherogram of the (C) the father (ACM8.1),  
(D) the mother (ACM 8.2)  and (E) the control 
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Samples ACM 8.5, 8.6, 8.7 and 8.8 displayed similar HRM profiles to that of the controls; Sanger 
sequencing confirmed that these family members were negative for this variant.  
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Figure 3.4: Identification of the c.1162 C>T PKP2 Exon 4 variant in the ACM 8 family members 
HRM showing the exon 4 derivative melt profiles of samples (A and B) ACM8.5 and a negative control; Sequencing 
electropherogram of samples (C) ACM8.5 and (D) the negative control  
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Figure 3.5: Pedigree of the ACM 8 family with ARVC. Circles represent females. Squares represent males. 
Clear circles and squares represent unaffected family members. Black circles and squares represent 
affected family members. Crossed symbols represent deceased members of the family. The circle in red 
represents a family member whose blood was not available for DNA analysis. 
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3.5 Discussion 
This investigation sought to validate the results of prior whole exome sequencing conducted on 
this family, in which a variant in PARVA was reported as the possible causative mutation 
(Mbele, 2014). Instead, our validation experiment identified variant known disease-causing 
mutation, PKP2 c.1162C>T, that was inherited in a homozygous state by the two severely 
affected siblings with ARVC.  
 
PKP2 encodes a protein which forms part of the cellular complex structure called the 
desmosome which is involved in intercellular adhesion and signaling in the epithelia and cardiac 
muscle (Green and Gaudry 2000) (Figure 3.6). PKP2 is also found in the nucleus, although its 
function in the nucleus is unknown (Schmidt and Jager 2005).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: An illustration of the cellular desmosomal structure with PKP2 shown amidst the other 
desmosomal proteins. (URL16) 
 
PKP2 mutations in 32 of 120 probands (27%) with ARVC of western European descent pointed 
to an important role of this gene in the pathogenesis of this disease (Gerull, Heuser et al. 2004). 
Mutations in PKP2  have been shown to cause ARVC (Gerull, Heuser et al. 2004, van der Zwaag, 
Cox et al. 2010, Zhang, Tavora et al. 2012, Li Mura, Bauce et al. 2013, Zhou, Chen et al. 2015) 
and it is estimated that these mutations account for 70% of all mutations associated with ARVC 
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(van Tintelen, Entius et al. 2006). The mutations generally appear to disrupt the desmosomal 
assembly and stability and even though the particular pathogenesis of PKP2 mutations in ARVC 
is hypothetical, it is speculated that disruption of cardiomyocytes in response to mechanical 
stretch or stress occurs, particularly in the triangle of dysplasia (right ventricular outflow tract, 
inferobasal area, and apex) because of impairment of cell-cell contact (Hall, Li et al. 2009).  
The c.1162C>T missense mutation causes the amino acid encoded to change from a hydrophilic 
arginine (R) to a hydrophobic tryptophan (W) at protein position 388, a change which may lead 
to instability of the whole protein because of the PKP2 protein unfolding (Wimley and White 
1996). This mutation is known to cause disease when a single mutant allele is present. It is 
noteworthy that the majority of white South Africans carrying this mutation are of Dutch 
descent (Watkins, Hendricks et al. 2009).  
 
When we correlate the genotype with the phenotype in this family we find that the individual 
with the heterozygous form of the PKP2 c.1162C>T mutation (the mother) displays a milder 
phenotype and later age of onset compare to the children who were homozygous for the PKP2 
c.1162C>T mutation with a more severe phenotype with a much earlier age of onset. We have 
previously observed this gene-dose effect in the context of compound heterozygous mutations 
in PKP2 (Watkins, Hendricks et al. 2009). The PKP2 mutation identified in ACM 8 occurred in 
exon 4 (Figure 3.7) of PKP2   
         
           c.1162C>T  
Figure 3.7: Figure showing the PKP2 mutation at exon 4 (URL12) 
 
Even though the original intention of this project was to validate the findings of a previous 
whole exome sequencing project, I found the true disease causing gene within this family.   
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We are aware that the original candidate gene screen on PKP2 in 2009 should have detected 
the c.1162C>T variant and will discuss how this variant could have been missed. Firstly, during 
the candidate gene screen carried out in 2009, only the student was responsible for analyzing 
hundreds of electropherograms at a time. The student had been trained and was considered to 
be experienced in reading the electropherograms- that practice was long since stopped. 
Secondly, the phenotype indicated that only the mother was affected, this led to a 
heterozygous autosomal dominant inheritance pattern suggested for this family where both 
affected siblings inherited the disease from the mother. This could also be the reason why the 
variant was missed during the UK whole exome sequencing data analysis; they were looking for 
a heterozygous variant and not a homozygous variant. We were not able to explore the 
Newcastle results as the raw data remained in Newcastle.  We will ask our Newcastle 
collaborators to confirm the presence of this variant in their Illumina data.  
It has to be noted that although both the Illumina and Ion Torrent platforms are NGS 
techniques, they operate on different principles, which could lead to a difference in 
performance(Salipante, Kawashima et al. 2014). In the Illumina platform DNA fragments are 
prepared for sequencing by bridge PCR which simultaneously amplifies single DNA molecules 
and covalently links amplicons to a solid substrate clusters. In contrast, Ion Torrent sequencing 
initially prepares templates by using emulsion PCR (Shendure and Ji 2008) whereby PCR 
reagents, primer-coated particles, and a low concentration of template fragments are 
combined with oil and emulsified to form picoliter-scale microreactions to achieve clonal 
amplification of single DNA molecules on the surfaces of individual particles(Shendure and Ji 
2008). In terms of data analysis Illumina favours resources that enable full analysis of their data 
at the location of data generation`, whereas end users employing Ion Torrent platform are able 
to access the data and share across working groups and used for large-scale customized 
analysis at sites other than where the data was generated (Glenn 2011). This variance between 
different platforms can also be affected by knowledge and experience of the bioinformatician 
analyzing the data. 
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In light of the homozygous mutation being missed above, we have since put laboratory 
practices in place that should avoid this scenario from occurring again: (1) All 
electropherograms are reviewed by a minimum of two experienced staff members and/or 
postgraduate students  (2) Due to the incomplete penetrance of ARVC and to avoid bias we 
have elected to filter all whole exome sequencing data for ARVC into autosomal dominant and 
autosomal recessive data streams regardless of the suggested inheritance pattern; this allows 
us to perform a more robust analysis.    
The future of genomic sequencing is very bright with the ability of NGS to integrate a diverse 
set of data analysis techniques into a single platform being a revolutionary development in the 
clinical field (Gullapalli, Desai et al. 2012). Nevertheless, it is still a young field and not much is 
known about it such as how to handle the large data sets being generated and the whole scope 
of their application and thus a concrete outline on the pitfalls of clinical NGS platform is a 
future prospect. 
 
 
 
 
  
 65 
 
Chapter 4: CONCLUSION 
A previous whole exome sequencing project completed in the United Kingdom (UK) in 2012 had 
identified PARVA as a candidate gene for cardiomyopathy in the ACM 8 family. We 
hypothesized that PARVA may harbor novel mutations that cause ARVC and other 
cardiomyopathies. With that in mind we set out to screen for PARVA mutations in all members 
of the ACM 8 family as well as in our cardiomyopathy cohorts (ARVC, DCM, HCM and RCM). We 
also wanted to validate the whole exome sequencing results obtained in the UK using the Ion 
Proton platform. 
Our screening results indicated that the PARVA c.392A>T variant was detected in three family 
members, two siblings (ACM 8.3 and ACM 8.4) who were severely affected  with ARVC at an 
early age and the mother (ACM 8.2) developed mild ARVC at a later age. The phenotypic 
variability seen within this family cannot be explained by the PARVA c.392A>T variant alone and 
called into question the causative role of PARVA within this family. In addition to the c.392A>T 
variant, Dr Mbele also found the variants PARVA c.523A>G and c.597T>G in two ARVC probands 
but these probands were later found not to meet the Task Force criteria for ARVC.  This casts 
doubt on the role of PARVA in cardiomyopathy.  In addition, during our screening, we found no 
pathogenic mutations in any of the 180 cardiomyopathy probands.  
The whole exome sequencing investigation sought to validate the results of prior whole exome 
sequencing conducted on this family, in which a variant in PARVA was reported as the possible 
causative mutation (Mbele, 2014). Instead, our validation experiment identified the known 
disease-causing mutation, PKP2 c.1162C>T, that was inherited in a homozygous state by the 
two severely affected siblings with ARVC.  This mutation was reported by Watkins as a founder 
mutation of ARVC amongst South Africans of European descent. It is noteworthy that the family 
in question is of Dutch descent, thus furthering the effect of this variant in causing ARVC and 
not the initially purported PARVA c.392A>T mutation.  
Although we found no evidence to support the causal role of PARVA in cardiomyopathy, this 
study was successful in identifying the causal mutation of the ARVC phenotype in this family. 
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Appendix 5: Bioinformatics tools methodology 
MutationTaster employs a Bayes classifier to eventually predict the disease potential of an 
alteration based on the input which is the name of the gene and the particular base alteration. 
The Bayes classifier calculates probabilities for the alteration to be either a disease mutation or 
a harmless polymorphism. The output is a probability value which represents the probability of 
the prediction whereby a value close to 1 indicates a high 'security' of the prediction 
SIFT prediction tool predicts the effect of a nonsynonymous coding single base variant and the 
input includes variant position and change in form of chromosomal coordinates. The 
coordinates are aligned against the Homo sapiens GRCh37 Ensembl63 assembly and the output 
is a prediction value which can either be damaging or tolerated with a SIFT score based on the 
effect of the variant on protein effect. 
PolyPhen-2 employs structural and comparative evolutionary considerations to predict the 
possible impact of amino acid substitutions on the stability and function of human proteins. It 
performs functional annotation of single-nucleotide polymorphisms (SNPs), maps coding SNPs 
to gene transcripts, extracts protein sequence annotations and structural attributes, and builds 
conservation profiles all made possible due to a high-quality multiple protein sequence 
alignment pipeline and a prediction method employing machine-learning classification. It then 
estimates the probability of the missense mutation being damaging based on a combination of 
all these properties. The prediction outcome can be one of benign, possibly damaging or 
probably damaging. A “Score” output accompanying the outcome is the probability of the 
substitution being damaging; “sensitivity” and “specificity” correspond to prediction confidence 
(Adzhubei, Jordan et al. 2013). 
 
